D (2010-2017)

STUDIES ON CONDITIONS and RELATED ARTICLES 2010-2017

*Articles/Studies in Pre-2000 List
+Articles/Studies in 2000-2009 List

DENTISTRY (See TEETH)
DEPRESSION*+
DERMATITIS*+
DEVIC’S DISEASE (See NEUROMYELITIS OPTICA)
DIABETES +
DIARRHEA
DOWN SYNDROME +
DRIVING AND CANNABIS*+
DRUG INTERACTIONS (See INTERACTIONS WITH OTHER DRUGS)
DRUG TESTING*+
DRUG TESTING-BLOOD / PLASMA*+
DRUG TESTING-BREATH TEST
DRUG TESTING – DETECTION OF DRUGS
DRUG TESTING–DIY CANNABINOID TESTING
DRUG TESTING-EDIBLES
DRUG TESTING-HAIR*+
DRUG TESTING-OTHER*+
DRUG TESTING-ORAL +
DRUG TESTING-QUALITY CONTROL (See Also SAFETY-ADULTERANTS)
DRUG TESTING-SECOND-HAND SMOKE (See METHODS OF USE-SECOND HAND SMOKE)
DRUG TESTING-URINE*+
DRUG TESTING-WASTEWATER / SEWAGE
DUPUYTREN’S CONTRACTURE +
DYSKINESIA*+
DYSPEPSIA*+
DYSTONIA*+
top


DEPRESSION
The use of Cannnabidiol (CBD) to Reduce Insomnia and the Urge To Use Alcohol in a Geriatric person in on going Behavior Therapy (case report–undated) http://cannabisclinicians.org/view-all-case-reports/entry/420/?pagenum=2
The use of Cannnabidiol (CBD) and Meditation to reduce Binge Drinking, Anxiety and to improve Emotional Regulation in Long Term Behavior Therapy (case report–undated) http://cannabisclinicians.org/view-all-case-reports/entry/437/?pagenum=2
Mixed mood disorder (case report–undated) http://cannabisclinicians.org/view-all-case-reports/entry/228/?pagenum=2
Harm Reduction: Alcohol Use Disorder, Cannabis-induced Psychotic Disorder and a tale of two Hemp Oils, in a Patient diagnosed with a Cluster A & B Personality Disorders in Long Term Behavior Therapy (case report–undated) http://cannabisclinicians.org/view-all-case-reports/entry/601/?pagenum=2
Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2866040/?tool=pubmed
Uni-Morbid and Co-Occurring Marijuana and Tobacco Use: Examination of Concurrent Associations with Negative Mood States (full–2010)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861285/?tool=pubmed
Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders? (full–2010)
http://www.scielo.br/pdf/rbp/v32s1/en_a04v32s1.pdf
Deficiency in Endocannabinoid Signaling in the Nucleus Accumbens Induced by Chronic Unpredictable Stress (full-2010)
http://www.nature.com/npp/journal/v35/n11/full/npp201099a.html
Depression-resistant endophenotype in mice overexpressing cannabinoid CB2 receptors (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936848/?report=classic
The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism (full–2010) http://www.mdpi.com/1424-8247/3/8/2647/htm
Brain CB2 Receptors: Implications for Neuropsychiatric Disorders (link to PDF–2010) http://www.mdpi.com/1424-8247/3/8/2517
Genes differentially expressed in CB1 knockout mice: involvement in the depressive-like phenotype (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20692131
Gadolinium-HU-308-incorporated micelles (full–2011) http://www.ncbi.nlm.nih.gov/books/NBK54067/pdf/CB2R-Gd-Micelles.pdf
Is lipid signaling through cannabinoid 2 receptors part of a protective system?
(full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/
Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085542/
N-palmitoylethanolamide, an endocannabinoid, exhibits antidepressant effects in the forced swim test and the tail suspension test in mice (full–2011) http://www.if-pan.krakow.pl/pjp/pdf/2011/3_834.pdf
Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21278728
top
Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Figure 1: n-3/n-6 PUFA dietary imbalance alters PUFAs level in mouse brain (charts–2011) http://www.nature.com/neuro/journal/v14/n3/fig_tab/nn.2736_F1.html
Endocannabinoid system dysfunction in mood and related disorders (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21916860
Intense exercise increases circulating endocannabinoid and BDNF levels in humans—Possible implications for reward and depression (abst–2011)
http://www.psyneuen-journal.com/article/PIIS0306453011002873/abstract?rss=yes
Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21497918
Cannabinoids and emotionality: a neuroanatomical perspective (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21827834
Testing bidirectional effects between cannabis use and depressive symptoms: moderation by the serotonin transporter gene (abst–2011) http://onlinelibrary.wiley.com/doi/10.1111/j.1369-1600.2011.00380.x/abstract
High on Life? Medical Marijuana Laws and Suicide (full–2012) http://ftp.iza.org/dp6280.pdf
Serum contents of endocannabinoids are correlated with blood pressure in depressed women (full–2012) http://www.lipidworld.com/content/pdf/1476-511X-11-32.pdf
Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts (full–2012) http://www.biomedcentral.com/1471-244X/12/112
Cannabinoid Receptor Genotype Moderation of the Effects of Childhood Physical Abuse on Anhedonia and Depression (full–2012)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706194/
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481531/
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities (full–2012)
http://rstb.royalsocietypublishing.org/content/367/1607/3353.full?sid=1569c370-cd5c-4358-89ff-857201f5e069
Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes (full–2012) http://journals.sagepub.com/doi/full/10.1177/0269881112454229
Effect of delta-9-tetrahydrocannabinol on behavioral despair and on presynaptic and postsynaptic serotonergic transmission (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22386778
Nature Against Depression (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22414105
Lower levels of cannabinoid 1 receptor mRNA in female eating disorder patients: Association with wrist cutting as impulsive self-injurious behavior (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22542985
Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22534181
top
The combined effects of parental divorce and parental history of depression on cannabis use in young adults in France (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22682099
Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes (abst–2012) http://jop.sagepub.com/content/26/10/1391
Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22990678
Essential fatty acids and lipid mediators. Endocannabinoids (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22730630
The CB(1) Receptor-Mediated Endocannabinoid Signaling and NGF: The Novel Targets of Curcumin (turmeric) (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22311129
Effect of dietary fat type on anxiety-like and depression-like behavior in mice (full–2013) http://www.springerplus.com/content/2/1/165
Cannabinoids, Neurogenesis and Antidepressant Drugs: Is there a Link? (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648779/
Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses (full–2013) http://www.biolmoodanxietydisord.com/content/3/1/19
Endocannabinoid system and mood disorders: Priming a target for new therapies (full–2013) http://www.sciencedirect.com/science/article/pii/S0278584612002801
A Randomized Double-blind, Placebo Controlled Trial of Venlafaxine-Extended Release for Co-occurring Cannabis Dependence and Depressive Disorders (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636166/
Low frequency stimulation evokes serotonin release in the nucleus accumbens and induces long-term depression via production of endocannabinoid (full-2013) http://jn.physiology.org/content/111/5/1046.long
The effects of anandamide signaling enhanced by the FAAH inhibitor URB597 on coping styles in rats (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830591/
The endocannabinoid system and emotional processing: A pharmacological fMRI study with ∆9-tetrahydrocannabinol (full–2013) http://www.europeanneuropsychopharmacology.com/article/S0924-977X%2813%2900195-8/fulltext
Cannabinoid Receptor Activation Prevents the Effects of Chronic Mild Stress on Emotional Learning and LTP in a Rat Model of Depression (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924526/
Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002665/
The neuroprotective effects of cocoa flavanol and its influence on cognitive performance (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575938/
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies (full–2013) http://www.karger.com/Article/FullText/350094
Can Marijuana Reduce Social Pain? (full–2013) http://journals.sagepub.com/doi/full/10.1177/1948550613488949
Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment (abst–2013) http://link.springer.com/article/10.1007%2Fs00213-013-2995-y
Additive effect of rimonabant and citalopram on extracellular serotonin levels monitored with in vivo microdialysis in rat brain (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23562616
Entopeduncular nucleus endocannabinoid system modulates sleep-waking cycle and mood in rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23584096
Additive effect of rimonabant and citalopram on extracellular serotonin levels monitored with in vivo microdialysis in rat brain (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23562616
Sleep Quality Moderates the Relation between Depression Symptoms and Problematic Cannabis Use among Medical Cannabis Users (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23721537
Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23844686
The endocannabinoid system and its possible role in neurobiology of psychiatric disorders (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24326750
Testing bidirectional effects between cannabis use and depressive symptoms: moderation by the serotonin transporter gene (abst–2013) http://onlinelibrary.wiley.com/doi/10.1111/j.1369-1600.2011.00380.x/abstract
top
Antidepressants and Changes in Concentration of Endocannabinoids and NAcylethanolamines in Rat Brain Structures (full–2014) http://download.springer.com/static/pdf/559/art%253A10.1007%252Fs12640 -014-9465-0.pdf?auth66=1395868546_998a8d5d87cb02529572689ff9213e4a&ext=.pdf
Genetic Variations in the Human Cannabinoid Receptor Gene Are Associated with Happiness (full–2014) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0093771
Therapeutic benefits of cannabis: a patient survey (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998228/
Effects of chaiyuwendan decoction on endocannabinoids levels in adipose tissue of rats with chronic stress-induced depression (full–2014) http://www.journaltcm.com/modules/Journal/contents/stories/141/16.pdf
Genetic Disruption of 2-Arachidonoylglycerol Synthesis Reveals a Key Role for Endocannabinoid Signaling in Anxiety Modulation (full–2014) http://www.cell.com/cell-reports/abstract/S2211-1247%2814%2900955-3?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124714009553%3Fshowall%3Dtrue
Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates (full–2014) http://www.futuremedicine.com/doi/full/10.2217/pgs.14.151
Therapeutic Potential of Inhibitors of Endocannabinoid Degradation for the Treatment of Stress-Related Hyperalgesia in an Animal Model of Chronic Pain (full–2014) http://www.nature.com/npp/journal/v40/n2/full/npp2014198a.html
Neural Effects of Cannabinoid CB1 Neutral Antagonist Tetrahydrocannabivarin (THCv) on Food Reward and Aversion in Healthy Volunteers (full–2014) http://ijnp.oxfordjournals.org/content/18/6/pyu094.long
Monoacylglycerol Lipase Inhibition Blocks Chronic Stress-Induced Depressive-Like Behaviors via Activation of mTOR Signaling (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023150/
Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain depressed behavior in rats (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963812/
Cannabinoid Transmission in the Prefrontal Cortex Bi-Phasically Controls Emotional Memory Formation via Functional Interactions with the Ventral Tegmental Area (full–2014) http://www.jneurosci.org/content/34/39/13096.long
top
The Endocannabinoid/Endovanilloid System and Depression (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243035/
Relationships between serotonergic and cannabinoid system in depressive-like behavior: a PET study with [11C]-DASB (full–2014) http://onlinelibrary.wiley.com/doi/10.1111/jnc.12716/full
Stress regulates endocannabinoid-CB1 receptor signaling (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247817/
Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696509/
Cannabinoid Type 1 Receptor Availability in the Amygdala Mediates Threat Processing in Trauma Survivors (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207337/
Cannabis use and suicidal ideations in high-school students (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25123343
Nutritional omega-3 modulates neuronal morphology in the prefrontal cortex along with depression-related behaviour through corticosterone secretion (full–2014) http://www.nature.com/tp/journal/v4/n9/full/tp201477a.html
Modulation of early stress-induced neurobiological changes: a review of behavioural and pharmacological interventions in animal models (full–2014) http://www.nature.com/tp/journal/v4/n5/full/tp201431a.html
Anti-depressive mechanism of repetitive transcranial magnetic stimulation in rat: The role of the endocannabinoid system (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24479995
Is there a role for palmitoylethanolamide in the treatment of depression? (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24630855
The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24861565
β-Caryophyllene, a CB2 Receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24930711
Paracetamol potentiates the antidepressant-like and anticompulsive-like effects of fluoxetine (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25340977
The association between cannabis use and mood disorders: A longitudinal study (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/25451420
Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24923339
Blockade of 2-arachidonoylglycerol hydrolysis produces antidepressant-like effects and enhances adult hippocampal neurogenesis and synaptic plasticity (full–2015) http://onlinelibrary.wiley.com/doi/10.1002/hipo.22344/full
High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity (full–2015) http://ijnp.oxfordjournals.org/content/early/2015/09/04/ijnp.pyv095.long
Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression? (full–2015) http://link.springer.com/article/10.1007/s00213-015-4105-9/fulltext.html
Chronic Adolescent Marijuana Use as a Risk Factor for Physical and Mental Health Problems in Young Adult Men (full-2015) http://www.ncbi.nlm.nih.gov/pubmed/26237286
Circulating endocannabinoids during hematopoietic stem cell transplantation: A pilot study (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476410/
Mechanisms of stress in the brain (abst–2015) http://www.nature.com/neuro/journal/v18/n10/full/nn.4086.html
Mechanisms of stress in the brain (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933289/
Cannabis use, depression and anxiety: A 3-year prospective population-based study (link to PDF–2015) http://www.jad-journal.com/article/S0165-0327%2815%2931030-2/abstract
Differential proteomic analysis of the anti-depressive effects of oleamide in a rat chronic mild stress model of depression (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25641667
Involvement of norepinephrine and serotonin system in antidepressant-like effects of oleoylethanolamide in the mice models of behavior despair (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25778418
top
The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs-A practical view (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25791296
For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders (abst–2015) http://www.sciencedirect.com/science/article/pii/S027858461500055X
Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: Mechanism of action and possible interactions with cholinergic system (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25660201
CB1 receptors modulate affective behaviour induced by neuropathic pain (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25863168
Antidepressant-like Effects of Oleoylethanolamide in a Mouse Model of Chronic Unpredictable Mild Stress (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25864425
Smoke Your Troubles Away: Exploring the Effects of Death Cognitions on Cannabis Craving and Consumption (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25950588
The endocannabinoid system role in the pathogenesis of obesity and depression (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26277182
A cannabinoid receptor 1 polymorphism is protective against major depressive disorder in methadone-maintained outpatients (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26331953
Endocannabinoid Modulation of Predator Stress-Induced Long-Term Anxiety in Rats (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26361059
Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26391492
Endocannabinoids and Mental Disorders (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26408164
Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1
receptor inverse agonist AM-251 after physical stress in mice (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26609670
Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants (abst–2015) http://www.eurekaselect.com/132200/article
Sex-dependence of anxiety-like behavior in cannabinoid receptor 1 (Cnr1) knockout mice (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26684509
The fatty acid amide hydrolase inhibitor URB597 modulates serotonin-dependent emotional behaviour, and serotonin1A and serotonin2A/C activity in the hippocampus (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26747370
Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26711860
top
Mediating processes between stress and problematic marijuana use (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25661989
Cannabinoid Receptors May Control Aversive Memories (news & abstract-2015) http://neurosciencenews.com/habenula-cb1-receptors-memory-2742/
Monoacylglycerol lipase inhibitors produce pro- or antidepressant responses via hippocampal CA1 GABAergic synapses (full–2016) http://www.nature.com/mp/journal/vaop/ncurrent/full/mp201622a.html
Cyclooxygenase-2 inhibition reduces stress-induced affective pathology (full–2016) https://elifesciences.org/content/5/e14137
Putative Epigenetic Involvement of the Endocannabinoid System in Anxiety- and Depression-Related Behaviors Caused by Nicotine as a Stressor (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942073/
Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects (full–2016) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0158779 Endocannabinoid-Mediated Plasticity in Nucleus Accumbens Controls Vulnerability to Anxiety after Social Defeat Stress (full–2016) http://www.cell.com/cell-reports/fulltext/S2211-1247(16)30851-8
Endocannabinoid signaling in social functioning: an RDoC perspective (full–2016) http://www.nature.com/tp/journal/v6/n9/full/tp2016169a.html
The relationship between cannabis use and measures of anxiety and depression in a sample of college campus cannabis users and non-users post state legalization in Colorado (full–2016) https://peerj.com/articles/2782/
Marijuana Compounds: A Nonconventional Approach to Parkinson’s Disease Therapy (full–2016) https://www.hindawi.com/journals/pd/2016/1279042/
Endocannabinoid system: Role in depression, reward and pain control (Review) (link to PDF–2016) https://www.spandidos-publications.com/10.3892/mmr.2016.5585
Treating Depression in Alcoholics (news & abst–2016) http://neurosciencenews.com/alcoholism-depression-psychology-3541/
Ketamine and MAG Lipase Inhibitor-Dependent Reversal of Evolving Depressive Behavior during Forced Abstinence from Alcohol Drinking (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26751284
Role of hypothalamic cannabinoid receptors in post-stroke depression in rats (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26778127
Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex – possible involvement of 5-HT1A and CB1 receptors (abst–2016) http://www.sciencedirect.com/science/article/pii/S0166432816300298
The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: a multi-target nutraceutical with therapeutic potential in neuro-psychiatric disorders (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26780936
Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26812919
top
Cannabidiol, neuroprotection and neuropsychiatric disorders (abst–2016) http://www.sciencedirect.com/science/article/pii/S1043661816000396
Placebo effect: clinical, biological and therapeutical involvements in depression (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26879253
Sex and age specific effects of delta-9-tetrahydrocannabinol during the periadolescent period in the rat: The unique susceptibility of the prepubescent animal (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26898326
Sevoflurane Prevents Stroke-induced Depressive and Anxiety Behaviors by Promoting Cannabinoid Receptor Subtype I-dependent Interaction Between β-Arrestin 2 and ERK1/2 in the Rat Hippocampus (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26991409 Gender Differences in Associations Between Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/26903256
Genetically reduced FAAH activity may be a risk for the development of anxiety and depression in persons with repetitive childhood trauma (abst–2016) http://www.europeanneuropsychopharmacology.com/article/S0924-977X(16)00077-8/abstract
Lipids in psychiatric disorders and preventive medicine (abst–2016) http://www.sciencedirect.com/science/article/pii/S0149763415303353
Bidirectional Associations Between Cannabis Use and Depressive Symptoms From Adolescence Through Early Adulthood Among At-Risk Young Men (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26997187
Exercise deprivation increases negative mood in exercise-addicted subjects and modifies their biochemical markers (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26812592
Medical marijuana use in head and neck squamous cell carcinoma patients treated with radiotherapy (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27005465
Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27023732
The association of specific traumatic experiences with cannabis initiation and transition to problem use: Differences between African-American and European-American women (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27012434
Dose-dependent cannabis use, depressive symptoms, and FAAH genotype predict sleep quality in emerging adults: a pilot study. (abst – 2016) http://www.ncbi.nlm.nih.gov/pubmed/27074158
Pharmacological inhibition of FAAH activity in rodents: a promising pharmacological approach for psychological – cardiac comorbidity? (abst–2016) http://www.sciencedirect.com/science/article/pii/S0149763416300318
Association between schizotypal and borderline personality disorder traits, and cannabis use in young adults (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27149691 Prohedonic Effect of Cannabidiol in a Rat Model of Depression (abst–2016) http://www.karger.com/Article/Abstract/443890
Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27262964
New Zealand Health Survey 2012/13: characteristics of medicinal cannabis users (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27349158
Anxiety, depression and risk of cannabis use: Examining the internalising pathway to use among Chilean adolescents (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27427415
The genetic basis of the comorbidity between cannabis use and major depression (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27517884
Anandamide reverses depressive-like behavior, neurochemical abnormalities and oxidative-stress parameters in streptozotocin-diabetic rats: Role of CB1 receptors (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27544303
Contribution of health motive to cannabis use among high-school students (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27543835
Chronic stress leads to epigenetic dysregulation of neuropeptide-Y and cannabinoid CB1 receptor in the mouse cingulate cortex (abst–2016) http://www.sciencedirect.com/science/article/pii/S0028390816304580
Chronic FAAH inhibition during nicotine abstinence alters habenular CB1 receptor activity and precipitates depressive-like behaviors (abst–2016) http://www.sciencedirect.com/science/article/pii/S0028390816304579
Targeting the Endocannabinoid System in Psychiatric Illness (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27811555
Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia (abst–2016) http://www.sciencedirect.com/science/article/pii/S0278584616302524
Sex-dependent influence of chronic mild stress (CMS) on voluntary alcohol consumption; study of neurobiological consequences (abst–2016) http://www.sciencedirect.com/science/article/pii/S0091305716302465
Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27919478
A dual inhibitor of FAAH and TRPV1 channels shows dose-dependent effect on depression-like behaviour in rats (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27938441
Marijuana Could Help Treat Drug Addiction and Mental Health Problems (news & abst–2016) http://neurosciencenews.com/addiction-mental-health-marijuana-5536/


DERMATITIS
Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20206138
Protective role of palmitoylethanolamide in contact allergic dermatitis (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/19909294
Comparative topical anti-inflammatory activity of cannabinoids and cannabivarins (abst–2010) http://www.sciencedirect.com/science/article/pii/S0367326X10000870
Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/
Endocannabinoid signaling and epidermal differentiation (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21628127
Molecular allergology in practice: an unusual case of LTP allergy (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/22360137
Differences in peripheral endocannabinoid modulation of scratching behavior in facial vs spinally-innervated skin (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394407/
The role of CB2 receptor ligands in human eosinophil function (full–2012) http://www.biomedcentral.com/content/pdf/2050-6511-13-S1-A13.pdf
Inhibitory effect of topical adelmidrol on antigen-induced skin wheal and mast cell behavior in a canine model of allergic dermatitis (full–2012) http://www.biomedcentral.com/1746-6148/8/230
Endocannabinoids limit excessive mast cell maturation and activation in human skin (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22226549
Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22738050
Cannabinoid 1 Receptors in Keratinocytes Modulate Proinflammatory Chemokine Secretion and Attenuate Contact Allergic Inflammation (full–2013) http://www.jimmunol.org/content/190/10/4929.long
Epigenetic Control of Skin Differentiation Genes by Phytocannabinoids (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23869687
Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23889474
The expression of cannabinoid receptor 1 is significantly increased in atopic patients (full–2014) http://www.jacionline.org/article/S0091-6749%2813%2902936-9/fulltext
Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis (full–2014) http://www.biomedcentral.com/1746-6148/10/21
TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24915599
TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240254/
Cannabinoid 1 receptors in keratinocytes attenuate FITC-induced mouse atopic-like dermatitis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24750433
Harnessing neuroendocrine controls of keratin expression: A new therapeutic strategy for skin diseases? (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24823963
Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26095080
top
Adelmidrol increases the endogenous concentrations of palmitoylethanolamide in canine keratinocytes and down-regulates an inflammatory reaction in an in vitro model of contact allergic dermatitis (abst–2015) http://www.sciencedirect.com/science/article/pii/S1090023315004712
Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model (full–2016) http://anndermatol.org/DOIx.php?id=10.5021/ad.2016.28.1.22
N-acyl ethanolamide and eicosanoid involvement in irritant dermatitis (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26947140
Dermatological Aspects of Synthetic Cannabinoid Addiction (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27028361
Anandamide Suppresses Proinflammatory T Cell Responses In Vitro through Type-1 Cannabinoid Receptor-Mediated mTOR Inhibition in Human Keratinocytes (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27694494
Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27720681
Targeting Cutaneous Cannabinoid Signaling in Inflammation – A “High”-way to Heal? (full–2017) http://www.ebiomedicine.com/article/S2352-3964(17)30003-8/fulltext
The Endocannabinoid System and Its Role in Eczematous Dermatoses (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28098721


DIABETES
Expression and function of cannabinoid receptors in mouse islets (full–2010) http://www.landesbioscience.com/journals/islets/LiISLETS2-5.pdf
Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845559/?tool=pmcentrez
Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005548/?tool=pubmed
Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy (full–2010) http://diabetes.diabetesjournals.org/content/59/4/1046.full?sid=0bc8e3fa-5275-4b19-8acc-4aec5dfac384
Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003779/
Cannabinoid Receptors are Coupled to Stimulation of Insulin Secretion from Mouse MIN6 β-cells (full–2010) http://www.karger.com/Article/Pdf/320527
Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868848/?tool=pubmed
Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients (full-2010) http://www.lipidworld.com/content/9/1/43
Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy (full-2010) http://www.natap.org/2010/newsUpdates/marijuana.pdf
A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes (full–2010) http://onlinelibrary.wiley.com/doi/10.1111/j.1463-1326.2009.01188.x/full
Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes? (full–2010) http://www.jci.org/articles/view/44099?search%5Babstract_text%5D=&search%5Barticle_text%5D=cannabinoid&search%5Bauthors_text%5D=&search%5Bfpage%5D=&search%5Btitle_text%5D=&search%5Bvolume%5D=
Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation (full–2010) http://www.wjgnet.com/1948-9358/full/v1/i1/12.htm
Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution (full–2010) http://www.eje-online.org/content/163/3/407.full
AMELIORATIVE POTENTIAL OF CANNABIS SATIVA EXTRACT ON DIABETES INDUCED NEUROPATHIC PAIN IN RATS (full–2010) http://www.ijpsr.com/V1I11/11%20Vol%201,%20Issue%2011,%20IJPSR,%20Paper%206.pdf
Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways (full–2010) http://diabetes.diabetesjournals.org/content/59/11/2826.full.pdf+html
top
A randomised, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GW42003 : GW42004 plus GW42003 and GW42004 alone in the treatment of dyslipidaemia in subjects with Type 2 diabetes (research summary–2010) http://www.hra.nhs.uk/news/research-summaries/gwmd1092-gw42003gw42004-together-plus-alone-intype-ii-diabetes/#sthash.FT2P6YcB.dpuf
American Diabetes Association–70th scientific sessions–research on novel therapeutics: part 2 (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20799137
Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20936991
Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20937249
AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20816753
Endocannabinoid (EC) Receptor, CB1, and EC Enzymes’ Expression in Primary Adipocyte Cultures of Lean and Obese Pre-pubertal Children in Relation to Adiponectin and Insulin (abst–2010) http://www.degruyter.com/abstract/j/jpem.2010.23.issue-10/jpem.2010.162/jpem.2010.162.xml?rskey=38kdx0&result=22&q=cannabinoid
G1359A polymorphism in the cannabinoid receptor-1 gene is associated with metabolic syndrome in the Chinese Han population (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20851297
GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/21094910
A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans (full–2011) http://joe.endocrinology-journals.org/content/211/2/177.long
Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161308/
Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082575/?tool=pubmed
top
Hepatic n-3 Polyunsaturated Fatty Acid Depletion Promotes Steatosis and Insulin Resistance in Mice: Genomic Analysis of Cellular Targets (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154437/
Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome (full–2011) http://ajpendo.physiology.org/content/300/4/E681.long
Variants at the endocannabinoid receptor CB1 gene (CNR1) and insulin sensitivity, type 2 diabetes, and coronary heart disease (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686489/
Altered endocannabinoid signalling after a high-fat diet in Apoe(-/-) mice: relevance to adipose tissue inflammation, hepatic steatosis and insulin resistance (full–2011) http://link.springer.com/article/10.1007/s00125-011-2274-6/fulltext.html
The association of the rs1049353 polymorphism of the CNR1 gene with hypo-adiponectinemia (full–2011) http://www.rjme.ro/RJME/resources/files/520311791795.pdf
Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085542/
GPR119 Regulates Murine Glucose Homeostasis Through Incretin Receptor-Dependent and Independent Mechanisms (full–2011) http://endo.endojournals.org/content/152/2/374.full?sid=c7413b30-1046-4f9c-b028-c46f78f293d9
Central Endocannabinoid Signaling Regulates Hepatic Glucose Production and Systemic Lipolysis (full–2011) http://diabetes.diabetesjournals.org/content/60/4/1055.full
Cannabinoids Inhibit Insulin Receptor Signaling in Pancreatic β-Cells (full–2011) http://diabetes.diabetesjournals.org/content/60/4/1198.full
TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both post-prandial and fasting hyperglycemia in type 2 diabetic rats (full–2011) http://jpet.aspetjournals.org/content/339/1/228.long
Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21340622
Expression of the cannabinoid system in muscle: effects of a high fat diet and CB1 receptor blockade (full–2011) http://www.biochemj.org/content/433/1/175
Role for cannabinoid receptors in human proximal tubular hypertrophy (full–2011) http://content.karger.com/produktedb/produkte.asp?DOI=000323997&typ=pdf
Cannabinoid receptor agonists and antagonists stimulate insulin secretion from isolated human islets of Langerhans (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/21564460/abstract/Cannabinoid_receptor_agonists_and_antagonists_stimulate_insulin_secretion_from_isolated_human_islets_of_Langerhans_
top
Endocannabinoid signaling and energy metabolism: a target for dietary intervention (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21470818
Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/21484568/abstract/Cannabinoids_and_Endocannabinoids_in_Metabolic_Disorders_with_Focus_on_Diabetes_
Win 55,212-2 reduces cardiac ischaemia-reperfusion injury in zucker diabetic fatty rats: role of cb2 receptors and cardiac inos/enos expression (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/21309057/abstract/Win_55212_2_reduces_cardiac_ischaemia_reperfusion_injury_in_zucker_diabetic_fatty_rats:_role_of_cb2_receptors_and_cardiac_inos/enos_expression_
Cannabidiol Dampens Streptozotocin-Induced Retinal Inflammation by Targeting of Microglial Activation (abst-2011) http://www.abstractsonline.com/plan/ViewAbstract.aspx?sKey=94b35de1-74b2-4d46-b062-7c104b5df681&cKey=eca34a2d-da44-4938-b0fa-3a6e652a1756
Functional and Structural Protection by N-Acylethanolamines in Diabetic Retinopathy (abst-2011) http://iovs.arvojournals.org/article.aspx?articleid=2356082&resultClick=1
Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289985/
The cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119 (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423238/
The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity (full–2012) http://diabetes.diabetesjournals.org/content/61/2/281.long
Endocannabinoids measurement in human saliva as potential biomarker of obesity (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409167/?tool=pubmed
Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500919/
Type 2 Diabetes Associated Changes in the Plasma Non-Esterified Fatty Acids, Oxylipins and Endocannabinoids (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493609/
Excess of the endocannabinoid anandamide during lactation induces overweight, fat accumulation and insulin resistance in adult mice (full–2012) http://www.dmsjournal.com/content/4/1/35
Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant (full–2012) http://www.nutritionj.com/content/11/1/50
Does rimonabant independently affect free fatty acid and glucose metabolism? (full–2012) http://www.ncbi.nlm.nih.gov/pubmed/22170727
Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoids (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372498/
top
Antihyperglycemic and hypolipidemic effects of α, β-amyrin, a triterpenoid mixture from Protium heptaphyllum in mice (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484111/
The Novel Reversible Fatty Acid Amide Hydrolase Inhibitor ST4070 Increases Endocannabinoid Brain Levels and Counteracts Neuropathic Pain in Different Animal Models (full–2012) http://jpet.aspetjournals.org/content/342/1/188.full.pdf+html
The Endocannabinoid System: Plant-Derived Cannabinoids in Diabetes and Diabetic Complications (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349875/
Fatty acid amide hydrolase ablation promotes ectopic lipid storage and insulin resistance due to centrally mediated hypothyroidism (full-2012) http://www.pnas.org/content/109/37/14966.long
Stimulating beta cell replication and improving islet graft function by GPR119 agonists (full–2012) http://onlinelibrary.wiley.com/doi/10.1111/j.1432-2277.2011.01332.x/full
Islet protection and amelioration of diabetes type 2 in Psammomys obesus by treatment with cannabidiol (link to PDF-2012) http://www.scirp.org/searchResult/Index.aspx?searchCode=Islet+protection+and+amelioration+of+diabetes+type+2+in+Psammomys+obesus+by+treatment+with+cannabidiol
Gut microbiota and the development of obesity (full–2012) http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112012000500007&lng=en&nrm=iso&tlng=en
Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22609797
Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22268426
Overexpression of cannabinoid CB2 receptor in the brain induces hyperglycaemia and a lean phenotype in adult mice (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22487302
Induction of Glucose Intolerance by Acute Administration of Rimonabant (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22678147
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22374408
A Randomized, Double-Blind, Placebo Controlled, Parallel Assignment, Flexible Dose, Efficacy Study of Nabilone as Adjuvant in the Treatment of Diabetic Peripheral Neuropathic Pain Using an Enriched Enrollment Randomized Withdrawal Design (S38.003) (abst–2012) http://www.neurology.org/cgi/content/meeting_abstract/78/1_MeetingAbstracts/S38.003?maxtoshow=&hits=25&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=180&sortspec=date&resourcetype=HWCIT
G1359A polymorphism in the cannabinoid receptor-1 gene is associated with the presence of coronary artery disease in patients with type 2 diabetes (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22138970
top
A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22669289
Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent (abst–2012)  http://www.ncbi.nlm.nih.gov/pubmed/22490067
An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22921260
The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22943701
Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22743603
Peripheral antinociceptive effect of anandamide and drugs that affect the endocannabinoid system on the formalin test in normal and streptozotocin-diabetic rats (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22959964
New vistas for treatment of obesity and diabetes? Endocannabinoid signalling and metabolism in the modulation of energy balance (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22674489
NEUROPROTECTIVE EFFECTS OF CANNABIS SATIVA ALCOHOLIC EXTRACT AGAINST SPINAL ALPHA MOTONEURONS DEGENERATION IN MALE TYPE II DIABETIC RATS (abst–2012) http://en.journals.sid.ir/ViewPaper.aspx?ID=278407
The impact of marijuana use on glucose, insulin, and insulin resistance among US adults (full–2013) http://www.amjmed.com/article/S0002-9343%2813%2900200-3/fulltext
Developmental Role for Endocannabinoid Signaling in Regulating Glucose Metabolism and Growth (full–2013) http://diabetes.diabetesjournals.org/content/62/7/2359.full?sid=2f5bda2b-a9c7-432a-9588-80c99189164d
Chronic activation of cannabinoid receptors in vitro does not compromise mouse islet function (full–2013) http://www.clinsci.org/cs/124/0467/1240467.pdf
Influence of G1359A polimorphysm of the cannabinoid receptor gene (CNR1) on insulin resistance and adipokines in patients with non alcoholic fatty liver disease (full–2013) http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112012000500039&lng=en&nrm=iso&tlng=en
The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671751/
Modulating the endocannabinoid system in human health and disease: successes and failures (full–2013) http://onlinelibrary.wiley.com/doi/10.1111/febs.12260/pdf
top
Reduced Food Intake is the Major Contributor to the Protective Effect of Rimonabant on Islet in Established Obesity-Associated Type 2 Diabetes (full–2013) http://www.eymj.org/DOIx.php?id=10.3349/ymj.2013.54.5.1127
Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese post-menopausal women. A MONET group study (full-2013) http://onlinelibrary.wiley.com/doi/10.1002/oby.20498/full
Insulin induces long-term depression of VTA dopamine neurons via endocannabinoids (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072656/
Is the cardiovascular system a therapeutic target for cannabidiol? (full–2013) http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2012.04351.x/full
The serine hydrolase ABHD6 Is a critical regulator of the metabolic syndrome (full–2013) http://www.cell.com/cell-reports/fulltext/S2211-1247%2813%2900507-X
Cannabinoid Receptor 2 Expression in Human Proximal Tubule Cells is Regulated by Albumin Independent of ERK1/2 Signaling (full-2013) http://www.karger.com/Article/Pdf/354529
A potential role for GPR55 in gastrointestinal functions (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660623/
A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1 (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794927/
Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554318/
Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600727/
Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes (full-2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920793/
Therapeutic Opportunities through the Modulation of Endocannabinoid Transport (full-2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255948/
TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791995/
Polymorphism rs3123554 in CNR2 reveals gender-specific effects on body weight and affects loss of body weight and cerebral insulin action (full-2013) http://onlinelibrary.wiley.com/doi/10.1002/oby.20573/full
Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice (full-2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949647/
Common polymorphism in the cannabinoid type 1 receptor gene (CNR1) is associated with microvascular complications in type 2 diabetes (full–2013) http://www.jdcjournal.com/article/S1056-8727%2813%2900199-2/fulltext
Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839776/
Medicinal Cannabis and Painful Sensory Neuropathy (editorial–2013) http://journalofethics.ama-assn.org/2013/05/oped1-1305.html
top
The complex effects of cannabinoids on insulin secretion from rat isolated islets of Langerhans (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23499687
Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23620336
Synergetic Insulin Sensitizing Effect of Rimonabant and BGP-15 in Zucker-Obes Rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23640247
Activation of type 2 cannabinoid receptors (CB2R) promotes fatty acid oxidation through the SIRT1/PGC-1α pathway (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23747418
Activation of spinal cannabinoid cb2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23892011
Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24120371
Biochemical and immunohistochemical changes in delta-9-tetrahydrocannabinol-treated type 2 diabetic rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23845579
Long-term supplementation of honokiol and magnolol ameliorates body fat accumulation, insulin resistance, and adipose inflammation in high-fat fed mice (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23901038
Islet cannabinoid receptors: cellular distribution and biological function (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24005231
Role of Genetic Variation in the Cannabinoid Receptor Gene (CNR1) (G1359A
Polymorphism) on Weight Loss and Cardiovascular Risk Factors After Liraglutide Treatment in Obese Patients With Diabetes Mellitus Type 2 (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24322329
Effects of C358A polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) on weight loss, adipocytokines levels, and insulin resistance after a high polyunsaturated fat diet in obese patients (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24445122
Fasiglifam as a new potential treatment option for patients with type 2 diabetes (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24195772
Docosahexaenoyl ethanolamide improves glucose uptake and alters endocannabinoid system gene expression in proliferating and differentiating C2C12 myoblasts (full–2014) http://journal.frontiersin.org/Journal/10.3389/fphys.2014.00100/full
A novel GPR40 agonist, CNX-011-67, suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161845/
Effect of intermittent cold exposure on brown fat activation, obesity, and energy homeostasis in mice (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895006/
Vascular targets for cannabinoids: animal and human studies (full–2014) http://onlinelibrary.wiley.com/doi/10.1111/bph.12560/full
top
The effects of obesity, diabetes and metabolic syndrome on the hydrolytic enzymes of the endocannabinoid system in animal and human adipocytes (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995979/
Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839256/
A new face of endocannabinoids in pharmacotherapy. Part II. Role of endocannabinoids in inflammation-derived cardiovascular diseases (full–2014) http://www.jpp.krakow.pl/journal/archive/04_14/pdf/183_04_14_article.pdf
Molecular matchmaking between the popular weight-loss herb Hoodia gordonii and GPR119, a potential drug target for metabolic disorder (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210048/
The G-Protein-Coupled Long-Chain Fatty Acid Receptor GPR40 and Glucose Metabolism (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176464/
Selected terpenoids from medicinal plants modulate endoplasmic reticulum stress in metabolic disorders (full–2014) http://onlinelibrary.wiley.com/doi/10.1111/jphp.12267/full
Glucose concentration in culture medium affects mRNA expression of TRPV1 and CB1 receptors and changes capsaicin toxicity in PC12 cells (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322151/
Optimization of GPR40 Agonists for Type 2 Diabetes (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027784/
Mitochondria: A Possible Nexus for the Regulation of Energy Homeostasis by the Endocannabinoid System? (full–2014) http://ajpendo.physiology.org/content/ajpendo/307/1/E1.full.pdf
Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy (full–2014) http://www.pnas.org/content/111/50/E5420.full?sid=66cd362f-ac53-47ba-920e-b7dae50940a2
Acute Activation of Cannabinoid Receptors by Anandamide Reduces Gastro-Intestinal Motility and Improves Postprandial Glycemia in Mice (full–2014) http://diabetes.diabetesjournals.org/content/64/3/808.long
Cannabidiol improves vasorelaxation in Zucker Diabetic fatty rats through cyclo-oxygenase activation (full–2014) http://jpet.aspetjournals.org/content/351/2/457.long
Cannabis use in relation to obesity and insulin resistance in the inuit population (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/oby.20973/full
A Role for Trans-caryophyllene in the Moderation of Insulin Secretion (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24486541
Glucose metabolism: Focus on gut microbiota, the endocannabinoid system and beyond  (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24631413
Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24827776
top
GPR55: From orphan to metabolic regulator? (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24972076
Physiology and therapeutics of the free fatty acid receptor GPR40 (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24373235
G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24234912
Selected CNR1 polymorphisms and hyperandrogenemia as well as fat mass and fat distribution in women with polycystic ovary syndrome (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25093427
Oxidative stress and cannabinoid receptor expression in type-2 diabetic rat pancreas following treatment with Δ9-THC (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25187240
Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25273317
Potential applications of marijuana and cannabinoids in medicine (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25518584
Elevated CB1 and GPR55 receptor expression in proximal tubule cells and whole kidney exposed to diabetic conditions (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25545857
Role of orphan G protein-coupled receptor 55 in diabetic gastroparesis in mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24964851
The antidiabetic and hepatoprotective effects of magnolol on diabetic rats induced by high-fat diet and streptozotocin (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24974464
Gastrointestinal hormonal responses on GPR119 activation in lean and diseased rodent models of type 2 diabetes (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24451185
α/β-Hydrolase Domain-6-Accessible Monoacylglycerol Controls Glucose-Stimulated Insulin Secretion (abst–2014) http://www.cell.com/cell-metabolism/abstract/S1550-4131%2814%2900166-1
Increased Plasma Levels of FABP4 and PTEN Is Associated with More Severe Insulin Resistance in Women with Gestational Diabetes Mellitus (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329941/
Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315049/
Changes in Plasma Levels of N-Arachidonoyl Ethanolamine and NPalmitoylethanolamine following Bariatric Surgery in Morbidly Obese Females with Impaired Glucose Homeostasis (full–2015) http://www.ncbi.nlm.nih.gov/pubmed/25874237
Fat Diet-Induced Insulin Resistance Does Not Increase Plasma Anandamide Levels or Potentiate Anandamide Insulinotropic Effect in Isolated Canine Islets (full–2015) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0123558
Atypical diabetic ketoacidosis: case report (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342127/
Role of the endocannabinoid system in obesity induced by neuropeptide Y over-expression in noradrenergic neurons (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423197/
top
Diacylglycerol lipase α knockout mice demonstrate metabolic and behavioral phenotypes similar to those of cannabinoid receptor 1 knockout mice (full–2015) http://journal.frontiersin.org/article/10.3389/fendo.2015.00086/full
Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation (full–2015) http://cardiovascres.oxfordjournals.org/content/early/2015/06/30/cvr.cvv179.long
N-Oleoyl glycine, a lipoamino acid, stimulates adipogenesis associated with activation of CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte (full–2015) http://www.sciencedirect.com/science/article/pii/S0006291X15305635
Cannabis – the Israeli perspective (full–2015) http://www.degruyter.com/view/j/jbcpp.ahead-of-print/jbcpp-2015-0091/jbcpp-2015-0091.xml
Circulating Endocannabinoids and the Polymorphism 385C>A in Fatty Acid Amide Hydrolase (FAAH) Gene May Identify the Obesity Phenotype Related to Cardiometabolic Risk: A Study Conducted in a Brazilian Population of Complex Interethnic Admixture (full–2015) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0142728
Cannabinoid CB1 receptors and mTORC1 signalling pathway interact to modulate glucose homeostasis (full–2015) http://dmm.biologists.org/content/9/1/51.long
Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH) (full–2015) http://cid.oxfordjournals.org/content/61/1/40.long
Dietary DHA reduced downstream endocannabinoid and inflammatory gene expression, epididymal fat mass, and improved aspects of glucose use in muscle in C57BL/6J mice (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722239/
Renal effects of chronic pharmacological manipulation of CB2 receptors in rats with dietinduced obesity (full–2015) http://onlinelibrary.wiley.com/enhanced/doi/10.1111/bph.13056
Alterations in the Medullary Endocannabinoid System Contribute to Age-related Impairment of Baroreflex Sensitivity (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424182/
Cannabis Smoking and Diabetes Mellitus: Results from Meta-analysis with Eight Independent Replication Samples (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801109/
Role of the Endocannabinoid System in Diabetes and Diabetic Complications (full–2015) http://onlinelibrary.wiley.com/doi/10.1111/bph.13226/full
Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5152762/
Endocannabinoid system activation may be associated with insulin resistance in women with polycystic ovary syndrome (full–2015) http://www.fertstert.org/article/S0015-0282(15)00232-0/fulltext
CB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptors (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609878/
Intake of farmed Atlantic salmon fed soybean oil increases hepatic levels of arachidonic acid-derived oxylipins and ceramides in mice (full–2015) http://www.jnutbio.com/article/S0955-2863(15)00021-2/fulltext
Marijuana use and risk of prediabetes and diabetes by middle adulthood: the Coronary Artery Risk Development in Young Adults (CARDIA) study (link to PDF-2015) http://link.springer.com/article/10.1007/s00125-015-3740-3
The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases (link to PDF–2015) http://www.degruyter.com/view/j/jbcpp.ahead-of-print/jbcpp-2015-0055/jbcpp-2015-0055.xml
GPR40 agonists for the treatment of type 2 diabetes: life after “TAKing” a hit (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25604916
Direct activation of the proposed anti-diabetic receptor, GPR119 in cardiomyoblasts decreases markers of muscle metabolic activity (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25578601
Influence of nitric oxide synthase or cyclooxygenase inhibitors on cannabinoids activity in streptozotocin-induced neuropathy (abst–2015)
http://www.ncbi.nlm.nih.gov/pubmed/25712641
Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25672659
Major urinary protein 1 interacts with cannabinoid receptor type 1 in fatty acid-induced hepatic insulin resistance in a mouse hepatocyte model (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25843798
top
Cannabinoid functions in the amygdala contribute to conditioned fear memory in streptozotocin-induced diabetic mice: interaction with glutamatergic functions (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25929688
Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids? (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26363623
New insights on the role of the endocannabinoid system in the regulation of energy balance (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26374449
Endocannabinoids and Metabolic Disorders (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26408168
Endocannabinoids and the Cardiovascular System in Health and Disease (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26408169
Deletion of G-protein coupled receptor 55 promotes obesity by reducing physical activity (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26447738
Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26646377
Endocannabinoids – at the crossroads between the gut microbiota and host metabolism  (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26678807
Blockade of Cannabinoid 1 Receptor Improves GLP-1R Mediated Insulin Secretion in Mice (abst–2015) http://www.sciencedirect.com/science/article/pii/S0303720715301714
G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26739335
GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges (abst–2015) http://www.eurekaselect.com/137697/article
Lipid signaling in adipose tissue: Connecting inflammation & metabolism (abst–2015) http://www.sciencedirect.com/science/article/pii/S1388198114002091
Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease (full–2016) http://www.hindawi.com/journals/np/2016/8373020/
Circulating Endocannabinoids and Insulin Resistance in Patients with Obstructive Sleep Apnea (full–2016) http://www.hindawi.com/journals/bmri/2016/9782031/
Cannabinoids Regulate Bcl-2 and Cyclin D2 Expression in Pancreatic β Cells (full– 2016) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0150981 New insights into the yin and yang of the endocannabinoid system in health and disease (full–2016) http://onlinelibrary.wiley.com/doi/10.1111/bph.13451/full
Mechanisms underlying glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854499/
Impaired Excitatory Neurotransmission in the Urinary Bladder from the Obese Zucker Rat: Role of Cannabinoid Receptors (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902197/
Metabolic Syndrome Among Marijuana Users in the United States: An Analysis of National Health and Nutrition Examination Survey Data (full–2016) http://www.amjmed.com/article/S0002-9343(15)01024-4/fulltext
Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes (abst–2016) http://link.springer.com/article/10.1007/s12192-015-0653-5
CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26757949
Prolonged activation of human islet cannabinoid receptors in vitro induces adaptation but not dysfunction (full–2016) http://www.sciencedirect.com/science/article/pii/S2214647416300137
The effect of spinally administered WIN 55,212-2, a cannabinoid agonist, on thermal pain sensitivity in diabetic rats (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887712/
Endocannabinoids in Feeding Behavior and Energy Homeostasis (full–2016) http://themedicalbiochemistrypage.org/endocannabinoids.php
Mice Expressing a “Hyper-Sensitive” Form of the Cannabinoid Receptor 1 (CB1) Are Neither Obese Nor Diabetic (full–2016) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0160462
Human CB1 Receptor Isoforms, present in Hepatocytes and β-cells, are Involved in Regulating Metabolism (full–2016) http://www.nature.com/articles/srep33302 Cannabis Use as Risk or Protection for Type 2 Diabetes: A Longitudinal Study of 18 000
Swedish Men and Women (full–2016) https://www.hindawi.com/journals/jdr/2016/6278709/
Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance (full–2016) http://link.springer.com/article/10.1007%2Fs12020-016-1172-6
Cannabinoid 2 Receptor Agonist Improves Systemic Sensitivity to Insulin in High-Fat Diet/Streptozotocin-Induced Diabetic Mice (full–2016) https://www.karger.com/Article/FullText/453171
α/β-Hydrolase Domain 6 in the Ventromedial Hypothalamus Controls Energy Metabolism Flexibility (full–2016) http://www.cell.com/cell-reports/fulltext/S2211-1247(16)31373-0
Endocannabinoid regulation of β-cell functions: Implications for glycemic control and diabetes (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045244/
Early Low Fat Diet Enriched with Linolenic Acid Reduces Liver Endocannabinoid Tone and Improves Late Glycemic Control After a High Fat Diet Challenge in Mice (full–2016) http://diabetes.diabetesjournals.org/content/65/7/1824.long
Effects of activation of endocannabinoid system on myocardial metabolism. (click “ICI” for download–2016) http://www.ncbi.nlm.nih.gov/pubmed/27333924
G protein-coupled receptor 18: A potential role for endocannabinoid signalling in metabolic dysfunction (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26337420
Impaired cued and spatial learning performance and altered cannabinoid CB1 receptor functionality in the substantia nigra in a rat model of diabetic neuropathy (abst–2016) http://www.sciencedirect.com/science/article/pii/S0166432816300249
β-Caryophyllene, a natural sesquiterpene lactone attenuates hyperglycemia mediated oxidative and inflammatory stress in experimental diabetic rats (abst–2016) http://www.sciencedirect.com/science/article/pii/S000927971530154X
Cannabinoid receptor type 1 mediates high-fat diet-induced insulin resistance by increasing forkhead box O1 activity in a mouse model of obesity (abst–2016) http://www.spandidos-publications.com/10.3892/ijmm.2016.2475
Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26337420
G protein-coupled receptor 18: A potential role for endocannabinoid signalling in metabolic dysfunction (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26337420
Cannabinoids and autoimmune diseases: A systematic review (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26876387
Role of cannabinoid receptors in renal diseases (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26968477
Endovanilloid control of pain modulation by the rostroventromedial medulla in an animal model of diabetic neuropathy (abst–2016) http://www.sciencedirect.com/science/article/pii/S002839081630079X
The role of carbon monoxide on the anti-nociceptive effects and expression of cannabinoid 2 receptors during painful diabetic neuropathy in mice (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27020787
Hierarchical glucocorticoid-endocannabinoid interplay regulates the activation of the nucleus accumbens by insulin (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27208730
Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26813930
Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27178047
Anandamide reverses depressive-like behavior, neurochemical abnormalities and oxidative-stress parameters in streptozotocin-diabetic rats: Role of CB1 receptors (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27544303
GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27561953
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo Controlled, Parallel Group Pilot Study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27573936
Marijuana Use and Type 2 Diabetes Mellitus: a Review (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27747490
Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27767974
Cannabinoid receptors and TRPA1 on neuroprotection in a model of retinal ischemia (abst–2016) http://www.sciencedirect.com/science/article/pii/S0014483516304791
Developmental Role of Macrophage Cannabinoid-1 Receptor Signaling in Type-2 Diabetes (abst–2017) http://diabetes.diabetesjournals.org/content/early/2017/01/11/db16-1199.long
top


DIARRHEA
Small intestinal cannabinoid receptor changes following a single colonic insult with oil of mustard in mice (full–2010) http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00132/full
Pharmacogenetic Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility in Patients with Non-Constipated Irritable Bowel Syndrome (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202649/
US Patent 7884133 B2 Cannabidiol derivatives such as 3-(2,6-dihydroxy-4- pentylphenyl)-4-prop-1-en-2-ylcyclohexene-1-carboxylic acid, used as as analgesics, antiinflammatory and antidiarrheal agents (full–2011) https://www.google.com/patents/US7884133?dq=patent+7884133&hl=en&sa=X&ei=Ujb0U_6EEIW5ogSl84LYDg&ved=0CB4Q6AEwAA Cannabis use amongst patients with inflammatory bowel disease (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21795981
Medical cannabis: the opportunity versus the temptation (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/22352284
Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775711/ Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial (full–2012) http://journals.sagepub.com/doi/full/10.1177/0269881111431623 Pro-resolution, protective and anti-nociceptive effects of a cannabis extract in the rat gastrointestinal tract (full–2013) http://www.jpp.krakow.pl/journal/archive/04_13/pdf/167_04_13_article.pdf
Cannabinoid Receptor 1 Gene and Irritable Bowel Syndrome: Phenotype and Quantitative Traits (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602676/
Effect of high fat-diet and obesity on gastrointestinal motility (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890396/ Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study (full–2013) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085073
Role of endogenous cannabinoid system in the gut (full-2013) http://www.actaps.com.cn/qikan/manage/wenzhang/2013-4-12.pdf
Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides (full–2014) http://onlinelibrary.wiley.com/doi/10.1111/nmo.12272/full
Cannabis for inflammatory bowel disease (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24969296 Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease (abst–2014) https://www.ncbi.nlm.nih.gov/pubmed/24407485 The long-term functional consequences of acute infectious diarrhea (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26628101
The role of cannabinoids in regulation of nausea and vomiting, and visceral pain (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25715910
May cannabinoids prevent the development of chemotherapy-induced diarrhea and intestinal mucositis? Experimental study in the rat (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27686064
Role of cannabinoids in gastrointestinal mucosal defense and inflammation (abst–2016) http://www.eurekaselect.com/140045/article
Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/26809974
Role of cannabis in digestive disorders (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27792038
Role of cannabis in digestive disorders (abst–2017) http://www.ingentaconnect.com/search/article?option1=tka&value1=cannabinoid&sortDescending=true&sortField=prism_publicationDate&pageSize=10 &index=3


DOWN SYNDROME
Gadolinium-HU-308-incorporated micelles (full–2011) http://www.ncbi.nlm.nih.gov/books/NBK54067/pdf/CB2R-Gd-Micelles.pdf
Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a (full-2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953590/
Monoacylglycerol Lipase Inhibitor JZL184 Improves Behavior and Neural Properties in Ts65Dn Mice, a Model of Down Syndrome (full-2014) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0114521
top


DRIVING AND CANNABIS
Sex Differences in the Effects of Marijuana on Simulated Driving Performance (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033009/?tool=pmcentrez
The effects of cannabis and alcohol on simulated arterial driving: Influences of driving experience and task demand (abst-2010) http://www.unboundmedicine.com/medline/ebm/record/20380913/abstract/The_effects_of_cannabis_and_alcohol_on_simulated_arterial_driving:_Influences_of_driving_experience_and_task_demand_
Medical Marijuana Laws, Traffic Fatalities, and Alcohol Consumption (full–2011) http://ftp.iza.org/dp6112.pdf
The prevalence of cannabis-involved driving in California (full–2011) http://www.sciencedirect.com/science/article/pii/S0376871611004741
Alcohol, psychoactive drugs and fatal road traffic accidents in Norway: a case-control study (abst-2011) http://www.unboundmedicine.com/medline/ebm/record/21376919/abstract/Alcohol_psychoactive_drugs_and_fatal_road_traffic_accidents_in_Norway:_a_case_control_study_
Psychomotor Performance, Subjective and Physiological Effects and Whole Blood Δ9-Tetrahydrocannabinol Concentrations in Heavy, Chronic Cannabis Smokers Following Acute Smoked Cannabis (full–2012) http://jat.oxfordjournals.org/content/36/6/405.full
A placebo-controlled study to assess Standardized Field Sobriety Tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid (full-2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456923/
The Therapeutic Potential of Cannabis and Cannabinoids (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442177/
Cannabis and psychomotor performance: A rational review of the evidence and implications for public policy (article-2012) http://www.letfreedomgrow.com/cmu/Armentano-Cannabis-and-psychomotor-performance.pdf
Cannabis use: a perspective in relation to the proposed UK drug-driving legislation (full-2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1588/full
Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers’ blood on per se drugged driving laws (full-2013) http://www.clinchem.org/content/59/3/519.full?sid=c00c9727-29e8-493c-83b8-456467e158b9
Prevalence of alcohol and other drugs and the concentrations in blood of drivers killed in road traffic crashes in Sweden (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/24265165
THCCOOH concentrations in whole blood: Are they useful in discriminating occasional from heavy smokers? (full-2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1581/full
Comparison between self-report of cannabis use and toxicological detection of THC / THCCOOH in blood and THC in oral fluid in drivers in a roadside survey (full-2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1517/full
Driving Under the Influence of Cannabis: Pitfalls, Validation, and Quality Control of a UPLC-MS/MS Method for the Quantification of Tetrahydrocannabinol in Oral Fluid Collected With StatSure, Quantisal, or Certus Collector (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/23318281
top
Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/23369054
Risk of severe driver injury by driving with psychoactive substances (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/23867258
Police custody following driving under the influence of cannabis: A prospective study (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/23890621
Blood Synthetic Cannabinoid Concentrations in Cases of Suspected Impaired Driving (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/23965292
Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/24129318
Analysis of AM-2201 and metabolites in a drugs and driving case (abst-2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1535/abstract
Analysis of AM-2201 and metabolites in a drugs and driving case (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24574312
Marijuana Policy in Colorado (full-2014) http://object.cato.org/sites/cato.org/files/pubs/pdf/working-paper-24_2.pdf
Adverse psychosocial outcomes associated with drug use among US high school seniors:
a comparison of alcohol and marijuana (full-2014) http://informahealthcare.com/doi/pdf/10.3109/00952990.2014.943371
Blood levels do not predict behavioral or physiological effects of Δ⁹-tetrahydrocannabinol in rhesus monkeys with different patterns of exposure (full-2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251811/
XLR-11 and UR-144 in Washington State and State of Alaska Driving Cases (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25217547
Cannabis Use and its Effects on Health, Education and Labor Market Success (link to PDF – 2014) http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2414469
An examination of the validity of the standardized field sobriety test in detecting drug impairment using data from the drug evaluation and classification program (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24345013
Driving under the influence of synthetic cannabinoids (“Spice”): a case series (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/23636569
The culpability of drivers killed in New Zealand road crashes and their use of alcohol and other drugs (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24636874
Determination of Δ9-tetrahydrocannabinolic acid A (Δ9-THCA-A) in whole blood and plasma by LC-MS/MS and application in authentic samples from drivers suspected of driving under the influence of cannabis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25173986
Cannabinoids determination in oral fluid by SPME-GC/MS and UHPLC-MS/MS and its application on suspected drivers (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25498928
Status Report: Marijuana Legalization in Colorado After One Year of Retail Sales and Two Years of Decriminalization (full–2015) http://www.drugpolicy.org/sites/default/files/Colorado_Marijuana_Legalization_One_Year_Status_Report.pdf
Drug and Alcohol Crash Risk (full–2015) http://kimabim.s3.amazonaws.com/812117-Drug_and_Alcohol_Crash_Risk.pdf
top
Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol (full–2015) http://www.clinchem.org/content/61/6/850.long
Comparing treatment effects of oral THC on simulated and on-the-road driving performance: testing the validity of driving simulator drug research (full–2015) http://link.springer.com/article/10.1007/s00213-015-3927-9/fulltext.html
Medical marijuana’s public health lessons–implications for retail marijuana in Colorado (full–2015) http://www.nejm.org/doi/full/10.1056/NEJMp1500043
Cannabis conundrum: Evidence of harm?: Opposition to marijuana use is often rooted in arguments about the drug’s harm to children and adults, but the scientific evidence is seldom clear-cut (article–2015) http://onlinelibrary.wiley.com/doi/10.1002/cncy.21516/full
Peaceful feeling, or up in smoke? Medical marijuana in medicolegal context (article–2015) http://www.mdedge.com/currentpsychiatry/article/102099/practice-management/peaceful-feeling-orsmoke-medical-marijuana
Drug-resistant MS spasticity treatment with Sativex® add-on and driving ability (full–2015) http://onlinelibrary.wiley.com/doi/10.1111/ane.12287/full
The Influence of Synthetic Cannabinoid UR-144 on Human Psychomotor Performance -A Case Report Demonstrating Road Traffic Risks (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25794331
Delays in DUI blood testing: Impact on cannabis DUI assessments (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26066003
Driving Under the Influence of Marijuana Versus Driving and Dying Under the Influence of Marijuana: A Comparison of Blood Concentrations of Δ9-Tetrahydrocannabinol, 11-Hydroxy-Δ9-Tetrahydrocannabinol, 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol and Other Cannabinoids in Arrested Drivers Versus Deceased Drivers (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26378132
Concentrations of AB-CHMINACA and AB-PINACA and Driving Behavior in Suspected Impaired Driving Cases (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26378139
Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26427296
Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/26653952
Ion mobility spectrometry for detection of Cannabis sativa L. metabolites from exhaled breath (abst-2015) https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0035-1565285
The impact of marijuana decriminalization on California drivers (abst-2015) http://www.drugandalcoholdependence.com/article/S0376-8716%2815%2900108-8/abstract
Restraint use and risky driving behaviors across drug types and drug and alcohol combinations for drivers involved in a fatal motor vehicle collision on U.S. roadways (full–2016) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819806/
Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues (full–2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00309/full
Dose of Reality: The Effect of State Marijuana Legalizations (report–2016) http://www.cato.org/publications/policy-analysis/dose-reality-effect-state-marijuana-legalizations#full
The effect of cannabis on regular cannabis consumers’ ability to ride a bicycle (abst-2016) http://www.ncbi.nlm.nih.gov/pubmed/26739323
Effect of Blood Collection Time on Measured Δ9-Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy (abst-2016) http://www.ncbi.nlm.nih.gov/pubmed/26823611
top
The Changing Drug Culture: Medical and Recreational Marijuana (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26881768
Cannabis effects on driving longitudinal control with and without alcohol (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26889769
The effects of cannabis intoxication on motor vehicle collision revisited and revised (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26878835
Traffic accidentability and risky driving behavior in young people in New Caledonia. Results of study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27259836
A multicenter retrospective survey of poisoning after consumption of products containing novel psychoactive substances from 2013 to 2014 in Japan (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27314752
State Medical Marijuana Laws and the Prevalence of Opioids Detected Among Fatally Injured Drivers (abst–2016) http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2016.303426?journalCode=ajph
Persistent cannabis dependence and alcohol dependence represent risks for midlife economic and social problems: A longitudinal cohort study (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/28008372
US Traffic Fatalities, 1985–2014, and Their Relationship to Medical Marijuana Laws (abst–2016) http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2016.303577
Self-reported Driving Under the Influence of Alcohol and Cannabis Among Ontario Students: Associations with Graduated Licensing, Risk Taking and Substance Abuse (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28095034
Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28138971


DRUG TESTING
Testing for cannabis in the work-place: a review of the evidence (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20402984
Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in “herbal high” products (full-2011) http://jat.oxfordjournals.org/content/34/5/252.long
Zinc Reduces the Detection of Cocaine, Methamphetamine, and THC by ELISA Urine Testing (full-2011) We need 8 to 11 mg of zinc daily; over 40 mg/day can cause zinc poisoning http://jat.oxfordjournals.org/content/35/6/333.long
Cannabinoids in postmortem toxicology (full–2011) http://jat.oxfordjournals.org/content/35/7/394.long
Postmortem redistribution of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OHTHC), and 11-nor-9-carboxy-THC (THCCOOH) (full-2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413259/
Prolonged excretion half-life of 11-nor-9-carboxy-Δ⁹-THC following cessation in a chronic, heavy marijuana user: implications for liver transplant assessment (1st page–2011) http://www.psychosomaticsjournal.com/article/S0033-3182%2810%2900028-9/abstract
Immunochemical approach using monoclonal antibody against Δ(9)-tetrahydrocannabinolic acid (THCA) to discern cannabis plants and to investigate new drug candidates (link to PDF-2011) http://www.benthamdirect.org/pages/content.php?CDDT/2011/00000008/00000001/002AR.SGM
A preliminary investigation on the distribution of cannabinoids in man (abst-2011) http://www.unboundmedicine.com/medline/ebm/record/21570784/abstract/A_preliminary_investigation_on_the_distribution_of_cannabinoids_in_man_
Prolonged excretion half-life of 11-nor-9-carboxy-Δ⁹-THC following cessation in a chronic, heavy marijuana user: implications for liver transplant assessment (1st page–2011) http://www.psychosomaticsjournal.com/article/S0033-3182%2810%2900028-9/abstract
Simultaneous determination of delta-9-tetrahydrocannabinol cannabidiol and cannabinol in edible oil using ultra performance liquid chromatography-tandem mass spectrometry (abst-2011) http://www.unboundmedicine.com/medline/ebm/record/21381415/abstract/%5BSimultaneous_determination_of_delta_9_tetrahydrocannabinol_cannabidiol_and_cannabinol_in_edible_oil_using_ultra_performance_liquid_chromatography_tandem_mass_spectrometry%5D_
Metabolic acidosis, hypoglycemia, and severe myalgias: an attempt to mask urine drug screen results (abst-2011) http://www.ncbi.nlm.nih.gov/pubmed/21467883
A placebo-controlled study to assess Standardized Field Sobriety Tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid (full-2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456923/
Cannabis misinterpretation and misadventure in a coroner’s court (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23155125
Cannabis misinterpretation and misadventure in a coroner’s court (full–2012) http://journals.sagepub.com/doi/full/10.1258/msl.2011.011087
Cannabis – from cultivar to chemovar (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22362625
top
Unexpected interference of baby wash products with a cannabinoid (THC) immunoassay (abst-2012) http://www.ncbi.nlm.nih.gov/pubmed/22465236
Detecting impairment associated with cannabis with and without alcohol on the Standardized Field Sobriety Tests (abst-2012) http://www.ncbi.nlm.nih.gov/pubmed/22763669
Are cannabis prevalence estimates comparable across countries and regions? A cross-cultural validation using search engine query data (abst-2012)
http://www.ncbi.nlm.nih.gov/pubmed/22809479
Does a positive finding of tetrahydrocannabinol in the blood result from ingestion of Indian frankincense (Boswellia serrata)? (abst-2012) http://www.unboundmedicine.com/medline/citation/22834359/%5BDoes_a_positive_finding_of_tetrahydrocannabinol_in_the_blood_result_from_ingestion_of_Indian_frankincense_%28Boswellia_serrata%29
Manual for use by national drug analysis laboratories Recommended methods for the Identification and Analysis of Synthetic Cannabinoid Receptor Agonists in Seized Materials (full–2013) http://www.unodc.org/documents/scientific/STNAR48_Synthetic_Cannabinoids_ENG.pdf
Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration (full-2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758774/
Identification and Structural Elucidation of Four Cannabimimetic Compounds (RCS-4, AM-2201, JWH-203 and JWH-210) in Seized Products (full–2013) http://jat.oxfordjournals.org/content/37/2/56.full.pdf+html
Elevated urine zinc concentration reduces the detection of methamphetamine, cocaine, THC and opiates in urine by EMIT (full–2013) Adults need 8 to 11 mg of zinc daily; over 40 mg/day can cause zinc poisoning http://jat.oxfordjournals.org/content/37/9/665.full Identification of Novel Third-Generation Synthetic Cannabinoids in Products by UltraPerformance Liquid Chromatography and Time-of-Flight Mass Spectrometry (full–2013) https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkt062
Marijuana Poisoning (dogs) (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23796481
Analysis of THCA synthase gene expression in cannabis: A preliminary study by realtime quantitative PCR (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23890639
An in vitro experiment on the interaction of charcoal or wheat bran with 11-nor-9-carboxy-Δ9-tetrahydrocannabinol and its glucuronide (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/24077855
Tricks and Tracks in the Identification and Quantification of Endocannabinoids (abst-2013) http://onlinelibrary.wiley.com/doi/10.1002/9780470015902.a0023407/abstract
Synthetic cannabinoid use among patients in residential substance use disorder treatment: Prevalence, motives, and correlates (full-2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161625/
An examination of the validity of the standardized field sobriety test in detecting drug impairment using data from the drug evaluation and classification program (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24345013
top
Metals and organic compounds in the biosynthesis of cannabinoids: a chemometric approach to the analysis of Cannabis sativa samples (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24483128
Workplace drug testing in Italy: Findings about second-stage testing (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24652693
Behaviours of psychotropic substances in indoor and outdoor environments of Rome, Italy (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24705952
Cocaine’s fall and marijuana’s rise: questions and insights based on new estimates of consumption and expenditures in US drug markets (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/25039446
A structure-reactivity relationship driven approach to the identification of a color test protocol for the presumptive indication of synthetic cannabimimetic drugs of abuse (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/25062530
Population Pharmacokinetic Model of THC Integrates Oral, Intravenous, and Pulmonary Dosing and Characterizes Short- and Long-term Pharmacokinetics (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/25316574
Simultaneous quantification of delta-9-THC, THC-acid A, CBN and CBD in seized drugs using HPLC-DAD (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/25005819
Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results (full-2015) http://jat.oxfordjournals.org/content/39/1/1.long
Non-smoker exposure to secondhand cannabis smoke II: Effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/25957157
Annual banned-substance review: analytical approaches in human sports drug testing (full-2015) http://onlinelibrary.wiley.com/doi/10.1002/dta.1769/full
A Reliable Method for the Separation and Detection of Synthetic Cannabinoids by Supercritical Fluid Chromatography with Mass Spectrometry, and Its Application to Plant Products (full-2015) https://www.jstage.jst.go.jp/article/cpb/63/10/63_c15-00170/_html
Emerging drugs of abuse: current perspectives on synthetic cannabinoids (full-2015)
https://www.dovepress.com/emerging-drugs-of-abuse-current-perspectives-on-synthetic-cannabinoidspeer-reviewed-fulltext-article-SAR
Seized cannabis seeds cultivated in greenhouse: A chemical study by gas chromatography–mass spectrometry and chemometric analysis (full-2015) http://www.scienceandjusticejournal.com/article/S1355-0306%2815%2900111-2/fulltext
Method for the Analysis of Cannabinoids and Terpenes in Cannabis (link to PDF–2015) http://tinyurl.com/z6j5xhe
A robust capillary liquid chromatography/tandem mass spectrometry method for quantitation of neuromodulatory endocannabinoids (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/26411510
Determination of 11 Cannabinoids in Biomass and Extracts of Different Varieties of Cannabis Using High-Performance Liquid Chromatography (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/26651563
Population Pharmacokinetic Model of THC Integrates Oral, Intravenous, and Pulmonary Dosing and Characterizes Short- and Long-term Pharmacokinetics (abst–2015) http://link.springer.com/article/10.1007/s40262-014-0195-5
top
Lipidomic Analysis of Endocannabinoid Signaling: Targeted Metabolite Identification and Quantification (full–2016) http://www.hindawi.com/journals/np/2016/2426398/ Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27400642 Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27005853
Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method (abst–2016) http://www.sciencedirect.com/science/article/pii/S0731708516302722
Extraction and Simultaneous Quantification of Endocannabinoids and Endocannabinoid Like Lipids in Biological Tissues (abst–2016) http://link.springer.com/protocol/10.1007%2F978-1-4939-3539-0_2
The Application of Voltammetric Analysis of Δ(9) -THC for the Reduction of False Positive Results in the Analysis of Suspected Marijuana Plant Matter (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27364289
Synthetic cannabinoids to avoid urine drug screens: Implications for contingency management and other treatments for drug dependence (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27424166
Use of Embryos Extracted from Individual Cannabis sativa Seeds for Genetic Studies and Forensic Applications (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27404624
Buying drugs on a Darknet market: A better deal? Studying the online illicit drug market through the analysis of digital, physical and chemical data (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27611957
Interpretation of Workplace Tests for Cannabinoids (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27686239
A systematic review of passive exposure to cannabis (abst–2016) http://www.fsijournal.org/article/S0379-0738(16)30493-5/abstract
top


DRUG TESTING-BLOOD/PLASMA
Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydro-cannabinol in blood and urine after passive exposure to Cannabis smoke in a coffee shop (full-2010) http://jat.oxfordjournals.org/content/34/4/196.long
Quantitation of Total 11-Nor-9-Carboxy-Delta 9-Tetrahydrocannabinol in Urine and Blood Using Gas Chromatography-Mass Spectrometry (GC-MS) (abst-2010) http://marijuana.researchtoday.net/archive/7/1/2746.htm
Interpretation of blood analysis data found after passive exposure to cannabis abst–2010) http://www.unboundmedicine.com/medline/ebm/record/20506708/abstract/%5BInterpretation_of_blood_analysis_data_found_after_passive_exposure_to_cannabis%5D_
Testing for cannabis in the work-place: a review of the evidence (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20402984
Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration (full–2011) http://www.clinchem.org/content/57/1/66.long
Oral Fluid and Plasma Cannabinoid Ratios after Around-the-Clock Controlled Oral [Delta]9-Tetrahydrocannabinol Administration (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836268/
Identification of Recent Cannabis Use:Whole-Blood and Plasma Free and Glucuronidated Cannabinoid Pharmacokinetics Following Controlled Smoked Cannabis Administration (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717336/
Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21116612
Variability of cannabinoid findings in blood (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21850885
Psychomotor Performance, Subjective and Physiological Effects and Whole Blood Δ9-Tetrahydrocannabinol Concentrations in Heavy, Chronic Cannabis Smokers Following Acute Smoked Cannabis (full–2012) http://jat.oxfordjournals.org/content/36/6/405.full
top
Detection and disposition of JWH-018 and JWH-073 in mice after exposure to “Magic Gold” smoke (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677765/
Determination of naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in mouse blood and tissue after inhalation exposure to ‘buzz’ smoke by HPLC/MS/MS (abst–2012) http://onlinelibrary.wiley.com/doi/10.1002/bmc.2710/abstract
Detection and quantification of new designer drugs in human blood: part 1 – synthetic cannabinoids (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22593567
Predictive model accuracy in estimating last Δ(9)-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC (abst–2012) http://www.sciencedirect.com/science/article/pii/S0376871612000798
Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction (abst–2012) http://onlinelibrary.wiley.com/doi/10.1002/jms.3020/abstract
Does a positive finding of tetrahydrocannabinol in the blood result from ingestion of Indian frankincense (Boswellia serrata)? (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22834359
Determination of the two major endocannabinoids in human plasma by μ-SPE followed by HPLC-MS/MS (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22847477
Distribution of free and conjugated cannabinoids in human bile samples (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22980143
Dried Blood Spots: Liquid chromatography-mass spectrometry analysis of Δ(9)-tetrahydrocannabinol and its main metabolites (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23228918
In Vitro Stability of Free and Glucuronidated Cannabinoids in Blood and Plasma Following Controlled Smoked Cannabis (full–2013) http://www.clinchem.org/content/59/7/1108.full?sid=c00c9727-29e8-493c-83b8-456467e158b9
Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers’ blood on per se drugged driving laws (full–2013) http://www.clinchem.org/content/59/3/519.full?sid=c00c9727-29e8-493c-83b8-456467e158b9
Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870889/
Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758774/
Plasma Cannabinoid Concentrations During Dronabinol Pharmacotherapy for Cannabis Dependence (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955404/
Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study (full–2013) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085073
Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24129318
THCCOOH concentrations in whole blood: Are they useful in discriminating occasional from heavy smokers? (full–2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1581/full
top
Simultaneous and sensitive LC–MS/MS determination of tetrahydrocannabinol and metabolites in human plasma (abst–2013) http://link.springer.com/article/10.1007/s00216-012-6501-x
Exercise increases plasma THC concentrations in regular cannabis users (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24018317
Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period (abst–2013) http://www.sciencedirect.com/science/article/pii/S000145751300362X
Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24202191
Prevalence of alcohol and other drugs and the concentrations in blood of drivers killed in road traffic crashes in Sweden (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24265165
Quantification of anandamide and 2-arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1561/full
Can Physical Exercise or Food Deprivation Cause Release of Fat-Stored Cannabinoids (full–2014) http://onlinelibrary.wiley.com/doi/10.1111/bcpt.12235/full
Performance, egg quality, and blood plasma chemistry of laying hens fed hempseed and hempseed oil (full–2014) http://ps.oxfordjournals.org/content/93/11/2827.long
Blood levels do not predict behavioral or physiological effects of Δ⁹-tetrahydrocannabinol in rhesus monkeys with different patterns of exposure (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251811/
Phase I and II Cannabinoid Disposition in Blood and Plasma of Occasional and Frequent Smokers Following Controlled Smoked Cannabis (full–2014)
http://www.clinchem.org/content/60/4/631.long
Fasting and exercise increase plasma cannabinoid levels in THC pre-treated rats: an examination of behavioural consequences (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24696079
A One-Step Extraction Procedure for the Screening of Cocaine, Amphetamines and Cannabinoids in Postmortem Blood Samples (abst-2014)
http://www.ncbi.nlm.nih.gov/pubmed/24782143
Determination of Δ9-tetrahydrocannabinolic acid A (Δ9-THCA-A) in whole blood and plasma by LC-MS/MS and application in authentic samples from drivers suspected of driving under the influence of cannabis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25173986
Spot them in the spot: analysis of abused substances using dried blood spots (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25383733
top
Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25127704
A quantitiative LC-MS/MS method for the measurement of arachidonic acid, prostanoids, endocannabinoids, N-acylethanolamines and steroids in human plasma (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25436483
Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol (full-2015) http://www.clinchem.org/content/61/6/850.long
Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects (full-2015) http://jat.oxfordjournals.org/content/39/7/497.long
Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users (full–2015) http://jat.oxfordjournals.org/content/39/8/580.long
High-throughput salting-out assisted liquid-liquid extraction with acetonitrile for the determination of anandamide in plasma of hemodialysis patients with liquid chromatography tandem mass spectrometry (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25622579
Residual cannabis levels in blood, urine and oral fluid following heavy cannabis use (abst–2015 http://www.ncbi.nlm.nih.gov/pubmed/25698515
Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25853390
Simultaneous determination of endocannabinoids in murine plasma and brain substructures by surrogate-based LC-MS/MS: Application in tumor-bearing mice (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25863017
Development of a simple and sensitive HPLC-UV method for the simultaneous determination of cannabidiol and Δ9-tetrahydrocannabinol in rat plasma (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26048666
Delays in DUI blood testing: Impact on cannabis DUI assessments (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/26066003
Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26097154
Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26257143
In vivo detection of the new psychoactive substance AM-694 and its metabolites (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26295909
Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids? (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26363623
Driving Under the Influence of Marijuana Versus Driving and Dying Under the Influence of Marijuana: A Comparison of Blood Concentrations of Δ9-Tetrahydrocannabinol, 11-Hydroxy-Δ9-Tetrahydrocannabinol, 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol and Other Cannabinoids in Arrested Drivers Versus Deceased Drivers (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26378132
Concentrations of AB-CHMINACA and AB-PINACA and Driving Behavior in Suspected Impaired Driving Cases (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26378139
top
Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26427296
Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26708108
In vitro stability of free and glucuronidated cannabinoids in blood and plasma collected in plastic gray-top sodium fluoride tubes following controlled smoked cannabis (abst–2015) http://link.springer.com/article/10.1007/s11419-015-0290-9
Development of a rapid column-switching LC-MS/MS method for the quantification of THCCOOH and THCCOOH-glucuronide in whole blood for assessing cannabis consumption frequency (abst–2016) http://link.springer.com/article/10.1007/s00216-016-9311-8
A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis (link to PDF–2016) https://www.dovepress.com/a-preliminary-evaluation-of-the-relationship-of-cannabinoid-blood-conc-peerreviewed-article-JPR
Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette (link to download–2016) https://ejournals.library.ualberta.ca/index.php/JPPS/article/view/28326/20877 Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27400642
Development of a rapid column-switching LC-MS/MS method for the quantification of THCCOOH and THCCOOH-glucuronide in whole blood for assessing cannabis consumption frequency (abst–2016) http://link.springer.com/article/10.1007/s00216-016-9311-8
Effect of Blood Collection Time on Measured Δ9-Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26823611
Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27005853
The therapeutic use of cannabinoids: Forensic aspects (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27038587
Drug Recognition Expert (DRE) examination characteristics of cannabis impairment (abst–2016) http://www.sciencedirect.com/science/article/pii/S0001457516301191
Optimized extraction of 2-arachidonyl glycerol and anandamide from aortic tissue and plasma for quantification by LC-MS/MS (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27274705
Analysis of Omega-3 Fatty Acid Derived N-Acylethanolamines in Biological Matrices (abst–2016) http://link.springer.com/protocol/10.1007%2F978-1-4939-3539-0_4 Identification of the oleic acid ethanolamide (OEA) isomer cis-vaccenic acid ethanolamide (VEA) as a highly abundant 18:1 fatty acid ethanolamide in blood plasma from rats and humans (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27334716
Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27345297 Cannabis Hyperemesis Syndrome in the Emergency Department: How Can a Specialized Addiction Team Be Useful? A Pilot Study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27485997
A novel microflow LC-MS method for the quantitation of endocannabinoids in serum (abst–2016) http://www.sciencedirect.com/science/article/pii/S1570023216306663 Assessing cannabis consumption frequency: Is the combined use of free and glucuronidated THCCOOH blood levels of diagnostic utility? (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27732768
Freeze-and-thaw stability and long-term-stability of 84 synthetic cannabinoids in serum (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27863089
A systematic review of passive exposure to cannabis. (abst – 2016) http://www.fsijournal.org/article/S0379-0738(16)30493-5/abstract
Free and Glucuronide Whole Blood Cannabinoids’ Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27899456
Dried haematic microsamples and LC-MS/MS for the analysis of natural and synthetic cannabinoids (abst–2016) http://www.sciencedirect.com/science/article/pii/S1570023216306171
Topical application of THC containing products is not able to cause positive cannabinoid finding in blood or urine (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28122323
Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28138971


DRUG TESTING-BREATH TEST
Detection of δ(9)-tetrahydrocannabinol in exhaled breath collected from cannabis users (full–2011) http://jat.oxfordjournals.org/content/35/8/541.long
Detection of drugs of abuse in exhaled breath from users following recovery from intoxication (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23045289
Cannabinoids in Exhaled Breath following Controlled Administration of Smoked Cannabis (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24046200
Application of drug testing using exhaled breath for compliance monitoring of drug addicts in treatment (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25562730
Method validation and application of a liquid chromatography-tandem mass spectrometry method for drugs of abuse testing in exhaled breath (full–2015) http://www.sciencedirect.com/science/article/pii/S1570023215000720
Ion mobility spectrometry for detection of Cannabis sativa L. metabolites from exhaled breath (abst–2015) https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0035-1565285
Δ9-Tetrahydrocannabinol concentrations in exhaled breath and physiological effects following cannabis intake – a pilot study using illicit cannabis (abst–2016) http://www.sciencedirect.com/science/article/pii/S0009912016300996
top


DRUG TESTING–DETECTION OF DRUGS
Potential exposures associated with indoor marijuana growing operations (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24116667
Detection of Illicit Drugs by Trained Honeybees (Apis mellifera) (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471073/
Development of Loop-Mediated Isothermal Amplification (LAMP) Assay for Rapid Detection of Cannabis sativa (link to PDF–2016) https://www.jstage.jst.go.jp/article/bpb/advpub/0/advpub_b16-00090/_article


DRUG TESTING–DIY CANNABINOID TESTING
DIY test to find high CBD plants grown from seeds (forum post–2015) http://forum.grasscity.com/medical-marijuana-usage-applications/1368614-diy-test-find-high-cbd-plantsgrown-seeds.html
Test THC and CBD at home (forum post–2015) http://www.marijuanagrowing.com/archive/index.php/t-8730.htm


DRUG TESTING-EDIBLES
Simultaneous determination of delta-9-tetrahydrocannabinol cannabidiol and cannabinol in edible oil using ultra performance liquid chromatography-tandem mass spectrometry (abst–2011) http://tinyurl.com/pmdcdp3
Simultaneous Analysis of Cannabinoid and Synthetic Cannabinoids in Dietary Supplements Using UPLC with UV and UPLC-MS-MS (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27185817
Stability of Tetrahydrocannabinol and Cannabidiol in Prepared Quality Control Medible Brownies (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27798074


DRUG TESTING-HAIR
Hair analysis for Delta9-tetrahydrocannabinolic acid A – new insights into the mechanism of drug incorporation of cannabinoids into hair (abst-2010) http://www.ncbi.nlm.nih.gov/pubmed/20129747
11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid ethyl ester (THC-COOEt): unsuccessful search for a marker of combined cannabis and alcohol consumption (abst–2010) http://tinyurl.com/z5ddjfg
A study on the concentrations of 11-nor-Δ(9)-tetrahydrocannabinol-9-carboxylic acid (THCCOOH) in hair root and whole hair (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21497466
A comparative study on the concentrations of 11-nor-Δ(9)-tetrahydrocannabinol-9-carboxylic acid (THCCOOH) in head and pubic hair (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21802874
Detection and quantification of 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid in hair by GC/MS/MS in Negative Chemical Ionization mode (NCI) with a simple and rapid liquid/liquid extraction (abst–2011) http://tinyurl.com/jplo6t7
The standardization of results on hair testing for drugs of abuse: An inter-laboratory exercise in Lombardy Region, Italy (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/22018743/abstract/The_standardization_of_results_on_hair_testing_for_drugs_of_abuse:_An_interlaboratory_exercise_in_Lombardy_Region_Italy_
Determination of 22 synthetic cannabinoids in human hair by liquid chromatography tandem mass spectrometry (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22835826
top
Simultaneous analysis of several synthetic cannabinoids, THC, CBD and CBN, in hair by ultra-high performance liquid chromatography tandem mass spectrometry. Method validation and application to real samples (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22576873
Monitoring of chronic Cannabis abuse: An LC-MS/MS method for hair analysis (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23305934
Development and validation of an LC-MS/MS method for quantification of Δ9-tetrahydrocannabinolic acid A (THCA-A), THC, CBN and CBD in hair (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23378095
Determination of cocaine, cocaine metabolites and cannabinoids in single hairs by MALDI Fourier transform mass spectrometry – preliminary results (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23386550
Deposition of JWH-018, JWH-073 and their metabolites in hair and effect of hair pigmentation (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24162819
Diagnostic Value of Concentration Profiles of Glucocorticosteroids and Endocannabinoids in Hair (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23942543
Methadone and illegal drugs in hair from children with parents in maintenance treatment or suspected for drug abuse in a German community (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24263638
Screening for synthetic cannabinoids in hair by using LC-QTOF MS: A new and powerful approach to study the penetration of these new psychoactive substances in the population (full–2014) http://msl.sagepub.com/content/54/1/22.long
Hair analysis for THCA-A, THC and CBN after passive in vivo exposure to marijuana smoke (full–2014) http://www.researchgate.net/publication/236185970_Hair_analysis_for_THCAA_THC_and_CBN_after_passive_in_vivo_exposure_to_marijuana_smoke
Utility of ELISA screening for the monitoring of abstinence from illegal and legal drugs in hair and urine (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1644/full
Utility of coloured hair for the detection of drugs and alcohol (full–2014)  http://onlinelibrary.wiley.com/doi/10.1002/dta.1654/full
Pediatric exposure to drugs of abuse by hair testing: monitoring 15 years of evolution in Spain (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143861/
Hair-based rapid analyses for multiple drugs in forensics and doping: application of dynamic multiple reaction monitoring with LC-MS/MS (full–2014) http://journal.chemistrycentral.com/content/8/1/73
top
Cannabinoid findings in children hair – what do they really tell us? An assessment in the light of three different analytical methods with focus on interpretation of Δ9-tetrahydrocannabinolic acid A concentrations (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1692/full
Proof of cannabis administration by sensitive detection of 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid in hair using selective methylation and application of liquid chromatography- tandem and multistage mass spectrometry (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1565/full
Workplace drug testing in Italy: Findings about second-stage testing (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24652693
Simultaneous determination of five naphthoylindole-based synthetic cannabinoids and metabolites and their deposition in human and rat hair (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25282599
Contribution of in utero drug exposure when interpreting hair results in young children (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25450508
Hair analysis as a tool to evaluate the prevalence of synthetic cannabinoids in different populations of drug consumers (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24115381
Ultra-structural hair alterations of drug abusers: a scanning electron microscopic investigation (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538045/
Hair analysis for Δ(9) -tetrahydrocannabinolic acid A (THCA-A) and Δ(9) -tetrahydrocannabinol (THC) after handling cannabis plant material (full–2015) http://onlinelibrary.wiley.com/doi/10.1002/dta.1830/full
Finding cannabinoids in hair does not prove cannabis consumption (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595642/
Determination of XLR-11 and its metabolites in hair by liquid chromatography-tandem mass spectrometry (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26070160
Comparison of cannabinoids in hair with self-reported cannabis consumption in heavy, light and non-cannabis users (full–2016) http://onlinelibrary.wiley.com/doi/10.1111/dar.12412/full
Assessment of rates of recanting and hair testing as a biological measure of drug use in a general population sample of young people (full–2016) http://onlinelibrary.wiley.com/doi/10.1111/add.13645/full
Evidence based decontamination protocols for the removal of external Δ9-tetrahydrocannabinol (THC) from contaminated hair (abst–2016) http://www.fsijournal.org/article/S0379-0738%2815%2900504-6/abstract
Metabolites of synthetic cannabinoids in hair-proof of consumption or false friends for interpretation? (abst–2016) http://link.springer.com/article/10.1007%2Fs00216-016-9422-2
Endocannabinoid concentrations in hair are associated with PTSD symptom severity (abst–2016) http://www.psyneuen-journal.com/article/S0306-4530%2816%2930040-3/abstract
Influence of thermal hair straightening on cannabis and cocaine content in hair (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26826847
Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27005853
Highly sensitive quantification of unconjugated 11-nor-9-carboxy-Δ9- tetrahydrocannabinol in a cannabis user’s hair using micropulverized extraction (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27020617
Contactless decontamination of hair samples: cannabinoids (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27074965
Simultaneous HPLC-APCI-MS/MS quantification of endogenous cannabinoids and glucocorticoids in hair (abst–2016) http://www.sciencedirect.com/science/article/pii/S1570023216303786
Detection and Mapping of Cannabinoids in single hair samples through rapid derivatization- Matrix-Assisted Laser Desorption Ionization Mass Spectrometry (abst–2016) http://pubs.acs.org/doi/abs/10.1021/acs.analchem.6b03551
A systematic review of passive exposure to cannabis (abst–2016) http://www.fsijournal.org/article/S0379-0738(16)30493-5/abstract
Comparative Evaluation of Drug Deposition in Hair Samples Collected from Different Anatomical Body Sites (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27979929 Drugs in hair. Part I. Metabolisms of major drug classes (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28119266


DRUG TESTING-OTHER
Drugs of abuse in airborne particulates in urban environments (abst-2010) http://www.unboundmedicine.com/medline/ebm/record/20447692/abstract/Drugs_of_abuse_in_airborne_particulates_in_urban_environments_
Versatile new ion source for the analysis of materials in open air under ambient conditions (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/15828760
Simultaneous analysis of frequently used licit and illicit psychoactive drugs in breast milk by liquid chromatography tandem mass spectrometry (abst-2011) http://www.ncbi.nlm.nih.gov/pubmed/21330091
top
Chemiluminescence detection of cannabinoids and related compounds with acidic potassium permanganate (abst-2012) http://www.ncbi.nlm.nih.gov/pubmed/22461321
The Current Status of Sweat Testing for Drugs of Abuse: A review (abst-2012) http://www.ncbi.nlm.nih.gov/pubmed/23244520
Detection of In Utero Marijuana Exposure by GC–MS, Ultra-Sensitive ELISA and LC–TOF–MS Using Umbilical Cord Tissue (full-2013) http://jat.oxfordjournals.org/content/early/2013/07/09/jat.bkt052.full
Simultaneous Quantification of Cocaine, Amphetamines, Opiates and Cannabinoids in Vitreous Humor (abst-2013) http://www.ncbi.nlm.nih.gov/pubmed/24225634
Potential exposures associated with indoor marijuana growing operations (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24116667
Detecting Cannabis Use on the Human Skin Surface via an Electronic Nose System (link to PDF-2014) http://www.mdpi.com/1424-8220/14/7/13256
An examination of the validity of the standardized field sobriety test in detecting drug impairment using data from the drug evaluation and classification program (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24345013
Can JWH-210 and JWH-122 be detected in adipose tissue four weeks after single oral drug administration to rats? (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24474420
Behaviours of psychotropic substances in indoor and outdoor environments of Rome, Italy (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24705952
Utilization of matrix-assisted laser desorption/ionization imaging mass spectrometry to search for cannabis in herb mixtures (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24838491
Meconium Drug Testing in Multiple Births in the USA (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24927721
Development and validation of a sensitive UPLC-ESI-MS/MS method for the simultaneous quantification of 15 endocannabinoids and related compounds in milk and other biofluids (abst–2014) http://pubs.acs.org/doi/abs/10.1021/ac403352e
Psychotropic substances in indoor environments (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24997305
Detection and mapping of illicit drugs and their metabolites in fingermarks by MALDI MS and compatibility with forensic techniques (full–2015) http://www.nature.com/srep/2015/150629/srep11716/full/srep11716.html
Finding cannabinoids in hair does not prove cannabis consumption (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595642/
Method for the Analysis of Cannabinoids and Terpenes in Cannabis  (link to PDF–2015) http://www.ingentaconnect.com/search/article?option1=tka&value1=cannabinoid&sortDescending=true&sortField=prism_publicationDate&pageSize=10&index=7
Detection of main metabolites of XLR-11 and its thermal degradation product in human hepatoma HepaRG cells and human urine (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25600155
top
Evaluation of an On-site Drug-testing Device for the Detection of Synthetic Cannabinoids in Illegal Herbal Products (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25759062
Distribution of ∆9-Tetrahydrocannabinol and 11-Nor-9-Carboxy-∆9 -Tetrahydrocannabinol Acid in Postmortem Biological Fluids and Tissues From Pilots Fatally Injured in Aviation Accidents (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/25800046
Comprehensive monitoring of the occurrence of 22 drugs of abuse and transformation products in airborne particulate matter in the city of Barcelona (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26081737
Quantitation of Synthetic Cannabinoids in Plant Materials Using High Performance Liquid Chromatography with UV Detection (Validated Method) (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26175160
Illicit psychotropic substances in the air: The state-of-art (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26360454
Development and validation of a LC/MS method for the determination of Δ9-tetrahydrocannabinol and 11-carboxy-Δ9-tetrahydrocannabinol in the larvae of the blowfly Lucilia sericata: Forensic applications (abst-2015) http://www.scienceandjusticejournal.com/article/S1355-0306%2815%2900073-8/abstract
The potential of infrared pupillography in routine police traffic checks (abst–2015) http://link.springer.com/article/10.1007/s00194-015-0023-8
Patterns of Drugs and Drug Metabolites Observed in Meconium: What Do They Mean? (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/25565668
Lipid Discovery by Combinatorial Screening and Untargeted LC-MS/MS (full–2016) http://www.nature.com/articles/srep27920
Brain 2-Arachidonoylglycerol Levels Are Dramatically and Rapidly Increased Under Acute Ischemia-Injury Which Is Prevented by Microwave Irradiation (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27021494
Drug Recognition Expert (DRE) examination characteristics of cannabis impairment (abst–2016) http://www.sciencedirect.com/science/article/pii/S0001457516301191
Cannabis Use Surveillance By Sweat Analysis (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27465974
Use of Embryos Extracted from Individual Cannabis sativa Seeds for Genetic Studies and Forensic Applications (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27404624 Determination of Drugs of Abuse in a Single Sample of Human Teeth by a Gas Chromatography-Mass Spectrometry Method (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27681340
A systematic review of passive exposure to cannabis (abst–2016) http://www.fsijournal.org/article/S0379-0738(16)30493-5/abstract
Evaluating a switch from meconium to umbilical cord tissue for newborn drug testing: A retrospective study at an academic medical center (abst–2016) http://www.sciencedirect.com/science/article/pii/S0009912016306087
Broad-Scale Genetic Diversity of Cannabis for Forensic Applications (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28107530
Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28138971


DRUG TESTING-ORAL
Patent 7816143 Oral detection test for cannabinoid use (full-2010) http://www.freepatentsonline.com/7816143.pdf
Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry (full-2010)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2849720/
Direct detection of Delta9-tetrahydrocannabinol in saliva using a novel homogeneous competitive immunoassay with fluorescence quenching (abst-2010) http://www.ncbi.nlm.nih.gov/pubmed/20103093
Oral Fluid and Plasma Cannabinoid Ratios after Around-the-Clock Controlled Oral [Delta]9-Tetrahydrocannabinol Administration (full-2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836268/
Synthetic cannabinoids in oral fluid (full-2011) http://jat.oxfordjournals.org/content/35/7/424.long
Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration (full-2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842229/
top
Cannabinoids in oral fluid following passive exposure to marijuana smoke (full-2011) http://www.clinchem.org/content/57/8/1127.long
Oral Fluid Cannabinoids in Chronic, Daily Cannabis Smokers During Sustained, Monitored Abstinence (full-2011) http://www.ncbi.nlm.nih.gov/pubmed/21677094
US Patent Application 20110020945 – ORAL DETECTION TEST FOR CANNABINOID USE (full-2011) http://www.freshpatents.com/-dt20110127ptan20110020945.php
A validated method for the detection and quantitation of 50 drugs of abuse and medicinal drugs in oral fluid by gas chromatography-mass spectrometry (abst-2011) http://www.ncbi.nlm.nih.gov/pubmed/21411382
A placebo-controlled study to assess Standardized Field Sobriety Tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid (full-2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456923/
Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration? (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612560/
Endocannabinoids measurement in human saliva as potential biomarker of obesity (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409167/?tool=pubmed
Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319321/
Ultra high performance liquid chromatography-electrospray ionization-tandem mass spectrometry screening method for direct analysis of designer drugs, “spice” and stimulants in oral fluid (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22939380
Influence of Ethanol on the Pharmacokinetic Properties of Δ9-Tetrahydrocannabinol in Oral Fluid (full–2013) http://jat.oxfordjournals.org/content/37/3/152.full
Current knowledge on cannabinoids in oral fluid (full–2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1514/full
11-Nor-9-carboxy-∆9-tetrahydrocannabinol quantification in human oral fluid by liquid chromatography-tandem mass spectrometry (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3773502/
Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758774/
Oral Fluid Cannabinoids in Chronic Cannabis Smokers during Oral Δ9-Tetrahydrocannabinol Therapy and Smoked Cannabis Challenge (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102264/
Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823692/
Detection of Synthetic Cannabinoids in Oral Fluid Using ELISA and LC-MS-MS (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23946452
Detection of Synthetic Cannabinoids in Oral Fluid Using ELISA and LC-MS-MS (full–2013) https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkt067
Comparison between self-report of cannabis use and toxicological detection of THC/THCCOOH in blood and THC in oral fluid in drivers in a roadside survey (full–2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1517/full
top
Driving Under the Influence of Cannabis: Pitfalls, Validation, and Quality Control of a UPLC-MS/MS Method for the Quantification of Tetrahydrocannabinol in Oral Fluid Collected With StatSure, Quantisal, or Certus Collector (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23318281
LC/ESI-MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windows (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23535743
Micro extraction by packed sorbent coupled to liquid chromatography tandem mass spectrometry for the rapid and sensitive determination of cannabinoids in oral fluids (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23806358
Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24202191
Stability of 11 prevalent synthetic cannabinoids in authentic neat oral fluid samples: glass versus polypropylene containers at different temperatures (abst–2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1497/abstract
Concordance of self-reported drug use and saliva drug tests in a sample of emergency department patients (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120967/
Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking. (full – 2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362971/
Quantitative Measurement of XLR11 and UR-144 in Oral Fluid by LC-MS-MS (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24812645
Assessment of different mouthwashes on cannabis oral fluid concentrations (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24453092
The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24699310
Evaluation of Δ9 -tetrahydrocannabinol detection using DrugWipe5S® screening and oral fluid quantification after Quantisal™ collection for roadside drug detection via a controlled study with chronic cannabis users (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24753449
Detection Time for THC in Oral Fluid after Frequent Cannabis Smoking (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24819969
Detection and Prevalence of Drug Use in Arrested Drivers Using the Dräger Drug Test 5000 and Affiniton DrugWipe Oral Fluid Drug Screening Devices (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24894458
Cannabinoids determination in oral fluid by SPME-GC/MS and UHPLC-MS/MS and its application on suspected drivers (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25498928
Current knowledge on cannabinoids in oral fluid (abst–2014) http://www.ingentaconnect.com/search/article;jsessionid=95az9ydub2yj.victoria?option1=tka&value1=cannabinoid&pageSize=10&index=6
top
Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26139312
Impact of oral fluid collection device on cannabinoid stability following smoked cannabis (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282833/
Residual cannabis levels in blood, urine and oral fluid following heavy cannabis use (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25698515
Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25853390
Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships (abst–2015)  http://www.ncbi.nlm.nih.gov/pubmed/26257143
Disposable screen printed sensor for the electrochemical detection of delta-9-tetrahydrocannabinol in undiluted saliva (full–2016) http://journal.chemistrycentral.com/content/10/1/1
Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette (link to download–2016) https://ejournals.library.ualberta.ca/index.php/JPPS/article/view/28326/20877
Water-compatible imprinted pills for sensitive determination of cannabinoids in urine and oral fluid (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26718187
Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27005853
Small Molecule Detection in Saliva Facilitates Portable Tests of Marijuana Abuse (abst–2016) http://pubs.acs.org/doi/abs/10.1021/acs.analchem.6b01688
Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27647820
Illicit Drugs in Oral Fluid: Evaluation of Two Collection Devices (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27681339
A systematic review of passive exposure to cannabis (abst–2016) http://www.fsijournal.org/article/S0379-0738(16)30493-5/abstract
Fluorescence-based lateral flow assays for rapid oral fluid roadside detection of cannabis use (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27862053


DRUG TESTING-QUALITY CONTROL
Chemists Analyze Cannabis For Safety And Potency (article–2013) http://cen.acs.org/articles/91/i49/Chemists-Analyze-Cannabis-Safety-Potency.html
Metagenomic analysis of medicinal Cannabis samples; pathogenic bacteria, toxigenic fungi, and beneficial microbes grow in culture-based yeast and mold tests (full–2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089129/ Analysis of a commerical marijuana e-cigarette formulation (abst–2016) (This article has a delayed release and will be available in PMC on June 1, 2017) https://www.ncbi.nlm.nih.gov/pubmed/27059691 Chapter 4 – Analytical Methods in Formulation Development and Manufacturing (abst–2016) http://www.sciencedirect.com/science/article/pii/B9780128046463000047 Chapter 5 – Quality Control and Stability Assessment (abst–2016) http://www.sciencedirect.com/science/article/pii/B9780128046463000059 Analysis of a Commercial Marijuana e-Cigarette Formulation (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27059691 Quality Control of Traditional Cannabis Tinctures: Pattern, Markers, and Stability (full–2017) http://www.mdpi.com/2218-0532/84/3/567/htm


DRUG TESTING-URINE
Urine Drug Screening: A Valuable Office Procedure (full–2010) http://www.aafp.org/afp/2010/0301/p635.html
Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815025/?tool=pubmed
Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to Cannabis smoke in a coffee shop (full-2010) http://jat.oxfordjournals.org/content/34/4/196.long
Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461262/pdf/nihms246130.pdf
top
Commonly prescribed medications and potential false-positive urine drug screens (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20689123
Testing for cannabis in the work-place: a review of the evidence (abst–2010)  http://www.ncbi.nlm.nih.gov/pubmed/20402984
Quantitation of Total 11-Nor-9-Carboxy-Delta 9-Tetrahydrocannabinol in Urine and Blood Using Gas Chromatography-Mass Spectrometry (GC-MS) (abst-2010) http://marijuana.researchtoday.net/archive/7/1/2746.htm
Detection of cannabigerol and its presumptive metabolite in human urine after Cannabis consumption (abst-2010) http://www.ncbi.nlm.nih.gov/pubmed/20614687
Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls (abst-2010) http://www.ncbi.nlm.nih.gov/pubmed/20872894
Liquid chromatography-tandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites (full–2011) http://jat.oxfordjournals.org/content/35/7/487.long
Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105467/
Zinc Reduces the Detection of Cocaine, Methamphetamine, and THC by ELISA Urine Testing (full–2011) We need 8 to 11 mg of zinc daily; over 40 mg/day can cause zinc poisoning http://jat.oxfordjournals.org/content/35/6/333.long
Prolonged excretion half-life of 11-nor-9-carboxy-Δ⁹-THC following cessation in a chronic, heavy marijuana user: implications for liver transplant assessment (1st page-2011) http://www.psychosomaticsjournal.com/article/S0033-3182%2810%2900028-9/abstract
A method for CP 47, 497 a synthetic non-traditional cannabinoid in human urine using liquid chromatography tandem mass spectrometry (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21233028
Evaluating the athlete’s claim of an unintentional positive urine drug test (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/23531893
Efavirenz interference in urine screening immunoassays for tetrahydrocannabinol (abst-2011) http://www.ncbi.nlm.nih.gov/pubmed/22067092
Adolescent Exposure of JWH-018 “Spice” Produces Subtle Effects on Learning and Memory Performance in Adulthood (full–2012) http://file.scirp.org/Html/2-3900080_19505.htm
Unresolved Discrepancies between Cannabinoid Test Results for Infant Urine (full–2012) http://www.clinchem.org/content/58/9/1364.full
Characterization of In Vitro Metabolites of CP 47,497, a Synthetic Cannabinoid, in Human Liver Microsomes by LC-MS/MS (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22931239
Impact of Lowering Confirmatory Test Cutoff Value in Pre-Enlistment Urine Cannabinoids Screening: About Five Years’ Experience in the French Gendarmerie (abst-2012) http://www.ncbi.nlm.nih.gov/pubmed/22933660
Comparison of Random and Postaccident Urine Drug Tests in Southern Indiana Coal Miners (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22895464
Unexpected interference of baby wash products with a cannabinoid (THC) immunoassay (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22465236
top
Qualitative Confirmation of 9 Synthetic Cannabinoids and 20 Metabolites in Human Urine Using LC-MS/MS and Library Search (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874406/
In Vitro Stability of Free and Glucuronidated Cannabinoids in Blood and Plasma Following Controlled Smoked Cannabis (full–2013) http://www.clinchem.org/content/59/7/1108.full?sid=c00c9727-29e8-493c-83b8-456467e158b9
Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703206/
Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography tandem mass spectrometry (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963402/
Efavirenz does not cause false-positive urine cannabis test in HIV-infected patients on Highly Active Anti-Retroviral Therapy (full–2013) http://www.e-mjm.org/2013/v68n3/Efavirenz.pdf
Urinary Cannabinoid Disposition in Occasional and Frequent Smokers: Is THC Glucuronide in Sequential Urine Samples a Marker of Recent Use in Frequent Smokers? (full–2013) http://www.clinchem.org/content/60/2/361.long
Evaluation of trends in marijuana toxicosis in dogs living in a state with legalized medical marijuana: 125 dogs (2005-2010) (full–2013) http://onlinelibrary.wiley.com/doi/10.1111/j.1476-4431.2012.00818.x/full
The accuracy of self-reported data concerning recent cannabis use in the French armed forces (full–2013) http://eurpub.oxfordjournals.org/content/23/2/328.long
Validation of a Novel Immunoassay for the Detection of Synthetic Cannabinoids and Metabolites in Urine Specimens (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23625703
Monitoring of urinary metabolites of JWH-018 and JWH-073 in legal cases (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23890611
Molecularly imprinted solid phase extraction for simultaneous determination of Δ(9)-tetrahydrocannabinol and its main metabolites by gas chromatography-mass spectrometry in urine samples (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23890655
Targeted Metabolomic Approach for Assessing Human Synthetic Cannabinoid Exposure and Pharmacology (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23987522
An in vitro experiment on the interaction of charcoal or wheat bran with 11-nor-9-carboxy-Δ9-tetrahydrocannabinol and its glucuronide (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24077855
Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23042760
Analysis of AM-2201 and metabolites in a drugs and driving case (abst–2013) http://onlinelibrary.wiley.com/doi/10.1002/dta.1535/abstract
Evaluation of trends in marijuana toxicosis in dogs living in a state with legalized medical marijuana: 125 dogs (2005-2010) (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23216842
Utility of ELISA screening for the monitoring of abstinence from illegal and legal drugs in hair and urine (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1644/full
Can Physical Exercise or Food Deprivation Cause Release of Fat-Stored Cannabinoids? (full–2014) http://onlinelibrary.wiley.com/doi/10.1111/bcpt.12235/full
top
In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259566/
Is urine an alternative to cosmetically treated hair for the detection of drugs and alcohol? (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1629/full
Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine (full-2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127333/
Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363290/ Enzyme-Linked Immunosorbent Assay (ELISA) for the Detection of Use of the Synthetic Cannabinoid Agonists UR-144 and XLR-11 in Human Urine (full–2014) https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bku049
Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1702/full
LC-QTOF-MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24424965
Workplace drug testing in Italy: Findings about second-stage testing (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24652693
UPLC-ESI-Q-TOF-MSE identification of urinary metabolites of the emerging sport nutrition supplement methoxyisoflavone in human subjects (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24742771
False-Positive Interferences of Common Urine Drug Screen Immunoassays: A Review (abst-2014) http://www.ncbi.nlm.nih.gov/pubmed/24986836
Cocaine’s fall and marijuana’s rise: questions and insights based on new estimates of consumption and expenditures in US drug markets (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25039446
Determination of major metabolites of MAM-2201 and JWH-122 in in vitro and in vivo studies to distinguish their intake (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25195129
Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25263309
Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results (full–2015) http://www.researchgate.net/publication/267043767_NonSmoker_Exposure_to_Secondhand_Cannabis_Smoke._I._Urine_Screening_and_Confirmation_Results
13-Year-Old Girl With Recurrent, Episodic, Persistent Vomiting: Out of the Pot and Into the Fire (full–2015) http://pediatrics.aappublications.org/content/135/4/e1060.long
13-Year-Old Girl With Recurrent, Episodic, Persistent Vomiting: Out of the Pot and Into the Fire (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25733759
Non-smoker exposure to secondhand cannabis smoke II: Effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects (full–2015) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747424/
Prevalence of psychotropic drug use in military police units (full–2015) http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413- 81232015000601843&lng=en&nrm=iso&tlng=en
Detection of main metabolites of XLR-11 and its thermal degradation product in human hepatoma HepaRG cells and human urine (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25600155
top
Detection Times of Carboxylic Acid Metabolites of the Synthetic Cannabinoids JWH-018 and JWH-073 in Human Urine (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25737323
Evaluation of an On-site Drug-testing Device for the Detection of Synthetic Cannabinoids in Illegal Herbal Products (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25759062
Residual cannabis levels in blood, urine and oral fluid following heavy cannabis use (abst–2015 http://www.ncbi.nlm.nih.gov/pubmed/25698515
Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25853390
Non-smoker exposure to secondhand cannabis smoke II: Effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25957157
Rapid elimination of Carboxy-THC in a cohort of chronic cannabis users (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26233612
Comparison of Common Immunoassay Kits for Effective Application in Workplace Drug Urinalysis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26270150
In vivo detection of the new psychoactive substance AM-694 and its metabolites (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26295909
Workplace drug testing on urine samples: evidence for improving efficacy of a first-level screening programme (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26384263
Analysis of Cannabinoids and Their Metabolites in Human Urine (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26411292
Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26427296
Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette (link to download–2016) https://ejournals.library.ualberta.ca/index.php/JPPS/article/view/28326/20877
Detecting biomarkers of secondhand marijuana smoke in young children (link to PDF– 2016) http://www.nature.com/pr/journal/vaop/naam/abs/pr2016261a.html
Water-compatible imprinted pills for sensitive determination of cannabinoids in urine and oral fluid (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26718187
Determination of urinary metabolites of XLR-11 by liquid chromatography–quadrupole time-of-flight mass spectrometry (abst–2016) http://link.springer.com/article/10.1007/s00216-015-9116-1
Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27005853
The therapeutic use of cannabinoids: Forensic aspects (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27038587
Metabolic patterns of JWH-210, RCS-4, and THC in pig urine elucidated using LC-HRMS/MS: Do they reflect patterns in humans? (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27328899
Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27345297
Synthetic cannabinoids to avoid urine drug screens: Implications for contingency management and other treatments for drug dependence (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27424166
Determination of cannabinoids in hemp nuts products in Taiwan by HPLC-MS/MS coupled with chemometric analysis: Quality evaluation and a pilot human study (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27590030
Adulterants in Urine Drug Testing (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27645818
Importance of Urinary Drug Screening in the Multiple Sleep Latency Test and Maintenance of Wakefulness Test (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27655451
Interpretation of Workplace Tests for Cannabinoids (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27686239
Topical application of THC containing products is not able to cause positive cannabinoid finding in blood or urine (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28122323
Immunoassay screening in urine for synthetic cannabinoids – an evaluation of the diagnostic efficiency (abst–2017) https://www.ncbi.nlm.nih.gov/pubmed/28130957


DRUG TESTING-WASTEWATER/SEWAGE
The current status of community drug testing via the analysis of drugs and drug metabolites in sewage (full–2011) http://www.ntnu.no/ojs/index.php/norepid/article/view/1421/1274
Evaluation of drugs of abuse use and trends in a prison through wastewater analysis (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/20655111/abstract/Evaluation_of_drugs_of_abuse_use_and_trends_in_a_prison_through_wastewater_analysis_
top
Evaluation of the presence of drugs of abuse in tap waters (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21664642
Evaluation of the presence of drugs of abuse in tap waters (abst–2011) http://www.sciencedirect.com/science/article/pii/S0045653511005868
Refining the estimation of illicit drug consumptions from wastewater analysis: coanalysis of prescription pharmaceuticals and uncertainty assessment (abst–2011) http://www.sciencedirect.com/science/article/pii/S0043135411003150
Profiles of illicit drug use during annual key holiday and control periods in Australia: wastewater analysis in an urban, a semi-rural and a vacation area (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23072541
Investigation of drugs of abuse and relevant metabolites in Dutch sewage water by liquid chromatography coupled to high resolution mass spectrometry (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22784865
Using quantitative wastewater analysis to measure daily usage of conventional and emerging illicit drugs at an annual music festival (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23782033
Using quantitative wastewater analysis to measure daily usage of conventional and emerging illicit drugs at an annual music festival (full–2013) http://onlinelibrary.wiley.com/doi/10.1111/dar.12061/full
Using biomarkers in wastewater to monitor community drug use: A conceptual approach for dealing with new psychoactive substances (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24412561
Illicit and abused drugs in sewage sludge: Method optimization and occurrence (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24275487
Wastewater analysis reveals regional variability in exposure to abused drugs and opioids in Finland (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24275228
Spatial differences and temporal changes in illicit drug use in Europe quantified by wastewater analysis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24861844
Improvements in analytical methodology for the determination of frequently consumed illicit drugs in urban wastewater (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24752696
Analysis of new classes of recreational drugs in sewage: Synthetic cannabinoids and amphetamine-like substances (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1461/full
Evaluation of the Efficacy of the Sewage Treatment Plant of Toledo, Spain in the Elimination of Drugs of Abuse and the Estimation of Consumption (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24914867
Application of a sewage-based approach to assess the use of ten illicit drugs in four Chinese megacities (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24485909
National study of illicit drug use in Slovakia based on wastewater analysis (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25046607
Trend analysis of anonymised pooled urine from portable street urinals in central London identifies variation in the use of novel psychoactive substances (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24506433
Occurrence and removal of drugs of abuse in Wastewater Treatment Plants of Valencia (Spain) (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25108491
Illicit drug consumption estimated by wastewater analysis in different districts of Milan: A case study (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25545943
Analysis of drugs of abuse by online SPE-LC high resolution mass spectrometry: Communal assessment of consumption (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25553546
top
Monitoring substance use in prisons: Assessing the potential value of wastewater analysis (abst–2014) http://www.scienceandjusticejournal.com/article/S1355-0306%2814%2900093-8/abstract
Detection of physiological activities of G protein-coupled receptor-acting pharmaceuticals in wastewater (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25556879
Simultaneous determination of 148 pharmaceuticals and illicit drugs in sewage sludge based on ultrasound-assisted extraction and liquid chromatography-tandem mass spectrometry (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25716466
Multi-residue determination of 10 selected new psychoactive substances in wastewater samples by liquid chromatography-tandem mass spectrometry (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26452866
Zerovalent iron and iron(VI): Effective means for the removal of psychoactive pharmaceuticals and illicit drugs from wastewaters (abst–2015)
http://www.ncbi.nlm.nih.gov/pubmed/26376114
Wastewater analysis and drugs — a European multi-city study (link to PDF–2016) http://www.emcdda.europa.eu/topics/pods/waste-water-analysis
Assessing geographical differences in illicit drug consumption-A comparison of results from epidemiological and wastewater data in Germany and Switzerland (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26896168
Population surveys compared with wastewater analysis for monitoring illicit drug consumption in Italy in 2010-2014 (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/26875670
Screening new psychoactive substances in urban wastewater using high resolution mass spectrometry (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27086019
Temporal trends in drug use in Adelaide, South Australia by wastewater analysis (abst–2016) http://www.sciencedirect.com/science/article/pii/S0048969716308853
Estimation of illicit drug use in the main cities of Colombia by means of urban wastewater analysis (abst–2016) http://www.sciencedirect.com/science/article/pii/S0048969716310087
Drugs of abuse and alcohol consumption among different groups of population on the Greek Island of Lesvos through sewage-based epidemiology (abst–2016) http://www.sciencedirect.com/science/article/pii/S0048969716308233
Estimating population size in wastewater-based epidemiology. Valencia metropolitan area as a case study (abst–2016) http://www.sciencedirect.com/science/article/pii/S0304389416305246
A comparison between wastewater-based drug data and an illicit drug use survey in a selected community (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27450319 Integrating environmental and self-report data to refine cannabis prevalence estimates in a major urban area of Switzerland (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27455466
Occurrence of illicit drugs and selected pharmaceuticals in Slovak municipal wastewater (abst–2016) http://link.springer.com/article/10.1007%2Fs11356-016-7415-5


DUPUYTREN’S CONTRACTURE
Dupuytren’s-The tumors are really shrinking (anecdotal/forum post-2013) http://forum.grasscity.com/medical-marijuana-usage-applications/1183263-dupuytrens-tumors-reallyshrinking.html
Dupuytren’s Contracture and Cannabis (news–2016) http://cannabishealthindex.com/uncategorized/dupuytrens-contracture-and-cannabis/


DYSKINESIA
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats (abst-2010) http://www.ncbi.nlm.nih.gov/pubmed/20888328
Tardive Dystonia and the Use of Cannabis (letter-forum repost-2010) http://www.420magazine.com/forums/dystonia/169902-tardive-dystonia-use-cannabis.html
Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21266946
Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia (full-2011) http://www.nature.com/tpj/journal/v12/n3/full/tpj201093a.html
Effects of cannabinoid CB(1) receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys (abst-2011) http://www.ncbi.nlm.nih.gov/pubmed/21029743
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/20888328/abstract/The_effects_of_cannabinoid_drugs_on_abnormal_involuntary_movements_in_dyskinetic_and_non_dyskinetic_6_hydroxydopamine_lesioned_rats_
Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors (abst–2011) http://www.neurobiologyofaging.org/article/S0197-4580%2809%2900116-X/abstract
top
The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273613/
Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24140894
The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273613/
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology (full–2014) http://www.neurology.org/content/82/17/1556.long
Cannabinoids: New Promising Agents in the Treatment of Neurological Diseases (full–2014) http://www.mdpi.com/1420-3049/19/11/18781/htm
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25486547
Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24599755
Anandamide attenuates haloperidol-induced vacuous chewing movements in rats (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24747871
The therapeutic potential of cannabinoids for movement disorders (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/25649017
Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism (link to PDF–2015) http://link.springer.com/article/10.1007/s00429-014-0823-8
Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26059564
Cannabinoids for the Treatment of Movement Disorders (abst–2015) http://www.ncbi.nlm.nih.gov/pubmed/26206230
Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics (abst–2015) http://link.springer.com/article/10.1007/s13311-015-0376-4
Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats (full–2016) http://journal.frontiersin.org/article/10.3389/fphar.2016.00343/full
Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action (abst–2016) https://www.researchgate.net/publication/304669756_Coadministration_of_cannabidiol_and_capsazepine_ reduces_L-DOPA-induced_dyskinesia_in_mice_Possible_mechanism_of_action


DYSPEPSIA
Increased Cerebral Cannabinoid-1 Receptor Availability Is a Stable Feature of Functional Dyspepsia: A [F]MK-9470 PET Study (full–2015) http://www.karger.com/Article/FullText/375454
Association between cerebral cannabinoid 1 receptor availability and body mass index in patients with food intake disorders and healthy subjects: a [(18)F]MK-9470 PET study (full–2016) http://www.nature.com/tp/journal/v6/n7/full/tp2016118a.html
top


DYSTONIA
Dronabinol for the treatment of unspecific pain, restlessness and spasticity in neuropaediatrics (abst–2010) https://www.thieme-connect.com/ejournals/abstract/10.1055/s-0030-1265622
Tardive Dystonia and the Use of Cannabis (letter/forum repost–2010) http://www.420magazine.com/forums/dystonia/169902-tardive-dystonia-use-cannabis.html
Effects of cannabinoid CB(1) receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21029743
Medical cannabis: the opportunity versus the temptation (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/22352284
Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia (abst-2015) http://www.ncbi.nlm.nih.gov/pubmed/26059564
Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia (full–2015) http://onlinelibrary.wiley.com/doi/10.1111/bph.13215/full
Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics (full–2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604174/
Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice (abst–2016) http://www.sciencedirect.com/science/article/pii/S1043661816302663
MEDICAL CANNABIS (abst–2016) http://www.ncbi.nlm.nih.gov/pubmed/27215115
Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3 (abst–2016) https://www.ncbi.nlm.nih.gov/pubmed/27717809